Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions

Leilei Fu\textsuperscript{a,1}, Wenke Jin\textsuperscript{a,†}, Jiahui Zhang\textsuperscript{b,c,1}, Lingjuan Zhu\textsuperscript{b,c}, Jia Lu\textsuperscript{d}, Yongqi Zhen\textsuperscript{a}, Lan Zhang\textsuperscript{a,*}, Liang Ouyang\textsuperscript{b}, Bo Liu\textsuperscript{b,*}, Haiyang Yu\textsuperscript{d,*}

\textsuperscript{a}Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China
\textsuperscript{b}State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China
\textsuperscript{c}College of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110064, China
\textsuperscript{d}State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China

Received 15 May 2021; received in revised form 5 July 2021; accepted 27 August 2021

Abstract

Drug repurposing or repositioning has been well-known to refer to the therapeutic applications of a drug for another indication other than it was originally approved for. Repurposing non-oncology small-molecule drugs has been increasingly becoming an attractive approach to improve cancer therapy, with potentially lower overall costs and shorter timelines. Several non-oncology drugs approved by FDA have been recently reported to treat different types of human cancers, with the aid of some new emerging technologies, such as omics sequencing and artificial intelligence to overcome the bottleneck of drug repurposing. Therefore, in this review, we focus on summarizing the therapeutic potential of non-oncology drugs, including cardiovascular drugs, microbiological drugs, small-molecule antibiotics, anti-viral drugs, anti-inflammatory drugs, anti-neurodegenerative drugs, antipsychotic drugs, antidepressants, and other drugs in human cancers. We also discuss their novel potential targets and relevant signaling pathways of these old non-oncology drugs in cancer therapies. Taken together, these inspiring findings will shed new light on repurposing more non-oncology small-molecule drugs with their intricate molecular mechanisms for future cancer drug discovery.

"Corresponding authors. Tel./fax: +86 28 85503817.
E-mail addresses: zhanglanx_9@126.com (Lan Zhang), liubo2400@163.com (Bo Liu), hyyu@tjutcm.edu.cn (Haiyang Yu).
†These authors made equal contributions to this work.
Peer review under responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

https://doi.org/10.1016/j.apsb.2021.09.006
2211-3835 © 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Cancer is a major factor affecting global health and is now the second leading cause of death worldwide. According to the global cancer statistics, there were an estimated 19.3 million new emerging cancer cases and almost 10.0 million cancer deaths occurred in 2020. With such high cancer-associated morbidity and mortality, more attention should be paid to the discovery of innovative treatments and effective drugs. Traditionally, discovery of de novo antitumor drugs involves extensive pre-clinical and clinical studies to determine the safety and efficacy of the drug. Thus, the median cost of cancer drug development was $648.0 million (range $157.3 million to $1950.8 million) and the average time was 10–17 years. Despite such investment, less than 1% of compounds are expected to enter clinical trials, let alone eventually come to market. Thus, there is an urgent need to promote the drug development process for cancer treatment.

Drug repurposing (also called drug repositioning, reprofiling or redirecting), which applies an ‘old’ drug or drugs with structural modification to a new indication, has emerged as an alternative strategy for the development of antitumor drugs. Compared with de novo drug creation, there is already a great of well-defined data in terms of safety, toxicity, and pharmacological properties of repurposed drugs. Thus, they can quickly pass preclinical and phase I clinical trials and transition rapidly to phase II and III clinical studies, and have higher probability of passing the clinical trial stage. Therefore, the time lag of research and development cycle can be reduced by 3–5 years and the costs by $0.3 billion.

Considering these advantages, drug repurposing could be an innovative strategy to identify effective agents for cancer treatment (Fig. 1A).

There are several successful cases of non-oncology drug repurposing for cancer therapy. For example, arsenic trioxide, a highly toxic substance that can be used for external skin erosion to remove decay, was first used to treat leukemia in 1972. Now arsenic trioxide injection combined with tretinoin has been approved by the FDA as a first-line treatment for acute promyelocytic leukemia (APL). Thalidomide, a classic case of repurposing a drug, was used for treating morning sickness during pregnancy but eventually withdrawn from the market because of its teratogenicity. Now, it is repurposed for refractory multiple myeloma excluding in pregnant women. Recently, metformin, a classic anti-diabetic II drug, is being intensively studied for its effects on many different cancers including prostate, pancreatic, breast, ovarian and endometrial cancer. These drugs represent good demonstrations of non-oncology drug repurposing for cancer therapy and show that drug repurposing might be a way to develop new antitumor drugs.

---

Figure 1  (A) The estimated time and main steps in traditional drug discovery and drug repurposing for cancer therapy. Traditional drug discovery for cancer therapy takes 10–17 years and drug repurposing takes only 3–12 years as it bypasses discovery of lead compound. (B) Main approaches of drug repurposing. There are mainly computational approaches including molecular docking, genetic association, pathway mapping, data mining, and signature matching as well as experimental approaches including phenotypic screening and binding assays for drug repurposing.
2. New emerging technologies for drug repurposing

Given the increase of drug repurposing, several new technologies, especially bioinformatics and computer technology, have emerged and greatly improved the process of drug repurposing research. As we all know, the first step of drug repurposing strategy is to find effective targets of disease, and select compounds from the Drug Repurposing Hub (an interactive drug repurposing database which contains a comprehensive library of drugs that have reached the clinic, www.broadinstitute.org/repurposing) by certain methods\textsuperscript{13}. Usually, the cancer genome database and other databases can be used to retrieve and screen the gene expression profile of the disease and proceed the enriched and the pathway analysis for differentially expressed genes to find their regulatory targets. Then, the optimal candidate compounds were calculated by Connectivity Map (CMap) ligatogram from numerous drug databases, such as PubChem, PharmGKB and DrugBank. Then, a pathway analysis and molecular docking can be conducted to evaluate the molecular mechanism of the candidate drug. Finally, the experiments \textit{in vitro} and \textit{in vivo} models are needed to validate their effects on new disease. With all these processes are finished, the drugs can carry out clinical trials to validate their pharmaceutical effects in human bodies\textsuperscript{14}. At present, approaches to drug repurposing are mainly either computational approaches or experimental approaches, both of which are increasingly being used simultaneously in most situations to improve the efficiency of repurposing drug research. Computational approaches like signature matching, molecular docking, genetic association, pathway mapping and data mining are helping to find new targets of the drug by exploit known targets, drugs, disease biomarkers or pathways. They involve systematic analysis of big data (such as gene expression, chemical structure, genotype, or proteomic data) to match new indications of old drugs. For example, signature matching is based on the comparison of characteristics of one drug with those of another drug, disease, or clinical phenotype for its transcriptomic, structural, or adverse effect profiles to identify the same mechanism to treat other disease. It contains drug–disease and drug–drug similarity approaches for the same chemical structures expressing similar biological activity. Molecular docking can predict binding site complementarity between the ligand and the target, and this is an inexpensive, simple, and efficient way to find target drugs by high throughput screening. It may be interrogated against a particular target by drug libraries or drug libraries can be explored against an array of target receptors. For instance, mebendazole, an anti-parasitic drug, has potential to inhibit vascular endothelial growth factor receptor 2 (VEGFR2) by

![Figure 2](image-url)
| Original indication | Name     | Cancer type                        | Mechanism                                                                 | Ref.     |
|---------------------|----------|------------------------------------|---------------------------------------------------------------------------|----------|
| Cardiovascular drugs| Losartan | Glioblastoma/Ovarian cancer        | Decompressing vessels by reducing solid stress/reducing cell proliferation and growth/apoptosis | 17,18    |
|                     | Irbesartan | Prostate cancer                    | Targeting the proinflammatory cytokines, oxidative stress, apoptosis and TGF-β1/STAT-3 signaling | 19      |
|                     | Valsartan | Gastric cancer/Hepatic cancer      | Targeting P38/AKT signaling                                               | 19      |
|                     | Telmisartan | Lung cancer/Gastric cancer        | WNT/β-catenin pathway                                                     | 20      |
|                     | Olmesartan | Breast cancer                      | Blocking RAS and NF-κB pathway leading to cytotoxicity and apoptosis      | 20      |
|                     | Captopril | Colorectal cancer/Glioblastoma     | Inhibiting angiogenesis and tumor invasion                                | 21      |
|                     | Enalapril | Colorectal cancer/Pancreatic cancer| Suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins | 22,23    |
|                     | Verapamil | Colorectal cancer/Breast cancer/Liver cancer | P-gp inhibitor                                                          | 24      |
|                     | Benazepril | Esophageal carcinoma/Gastrointestinal cancers | Inhibiting the cell growth                                               | 25      |
|                     | Carvedilol | Glioblastoma/Pancreatic cancer/Breast cancer | Inducing mitochondrial damage/inhibiting cell proliferation and migration | 26,27    |
|                     | Propranolol | Hemangioma/Melanoma/Prostate cancer | Inhibiting angiogenesis and migration of cancer cells/interfering SOX18 transcriptional activity for cancer therapy | 28,29    |
|                     | Atenolol | Gastric cancer                      | Inhibiting apoptosis, proliferation, migration and inflammatory cell responses for cancer therapy | 30      |
|                     | Digoxin | Pulmonary tumor/Prostate cancer/Breast cancer/Glioblastoma/Leukemia | Inhibiting Na+/K+ ATPase/apoptosis/suppressing HIF-1α accumulation/reducing ERK pathway/inducing expression of P21Cip1 | 31–34 |
|                     | Pitavastatin | Glioblastoma                      | Inhibiting mevalonate pathway/suppressing tumor cell MDR-1 protein and cell proliferation | 35,36    |
|                     | Simvasatatin | Glioblastoma                      | Inhibiting cell proliferation and migration/apoptosis via increasing caspase-3 activity/downregulating the P38/AKT pathway | 36      |
|                     | Mevasatatin | Glioblastoma                      | Inhibiting cell proliferation/apoptosis via suppressing RAS/ERK and P38/AKT pathways | 37      |
|                     | Fluvastatin | Breast cancer/ Renal cancer       | mTOR pathway/P21                                                         | 38      |
|                     | Atorvasatin | Glioblastoma                      | Inhibiting proliferation, migration and invasion/downregulating MMP via P38 MAPK pathway/apoptosis via caspase-8 and caspase-3 pathway| 39      |
|                     | Lovastatin | Glioblastoma                      | Inhibiting cell proliferation and MAPK pathway to induce apoptosis/increasing G0/G1 cell arrest | 40      |
|                     | Cerivastatin | Glioblastoma                      | Downregulating FAK phosphorylation to inhibit cell adhesion and invasion | 39      |
| Microbiological agents | Ticlopidine | Glioblastoma                      | Autophagy                                                               | 41      |
|                     | Prazosin | Glioblastoma                      | Apoptosis via activating caspase-3                                        | 42      |
|                     | Fenofibrate | Colon cancer                       | PPAR-α                                                                  | 43      |
|                     | Verapamil | Glioblastoma                      | Inducing apoptosis by increasing the BAX/BCL-2 ratio                      | 42      |
|                     | Sildenafil | Glioblastoma                      | Increasing BBTB permeability via cGMP pathway                            | 43      |
|                     | Chloroquine | Glioblastoma/Pancreatic cancer | Autophagy/inhibiting MMP-2 activity, cell proliferation and invasion | 44      |
|                     | Hydroxychloroquine | Cancer                   | Autophagy                                                               | 44      |
|                     | Mefloquine | Glioblastoma                      | Inhibiting cell proliferation via inducing cell cycle arrest in G2/M phase/autophagy | 44      |

*Table 1 Repurposing non-oncology small-molecule drugs for cancer therapy.*
| Original indication | Name | Cancer type | Mechanism | Ref. |
|--------------------|------|-------------|-----------|-----|
| **Artemisinin**    | Breast cancer | Caspase-dependent apoptosis/STAT3 | 45,46 |
| **Dihydroartemisinin** | Cancer | Inducing oxidative stress response by reactive oxygen species and nitric oxide, DNA damage | 45,46 |
| **Artesunate** | Cancer | Inhibiting angiogenesis and tumor-related signal transduction pathways | 45,46 |
| **Artemether** | Cancer | Apoptosis, autophagy and ferroptosis | 45,46 |
| **Arteether** | Cancer | Targeting NF-κB, MYC/MAX, AP-1, CREBP | 45,46 |
| **Daraprim** | Triple-negative breast cancer | STAT3 inhibitor | 47 |
| **Quinacrine** | Glioblastoma | Apoptosis and autophagy | 48 |
| **Amodiaquine** | Melanoma | Apoptosis and autophagy | 49 |
| **Artefenomel** | Cancer | Regulating the PD-L1 to PD-1 axis for establishing CD4+ T cell immunity | 50 |
| **Itraconazole** | Prostate cancer/Glioblastoma/Non-small cell lung cancer/Liver cancer/Gastric cancer | Inhibiting hedgehog pathway, AKT--mTOR pathway and angiogenesis | 51,52 |
| **Posaconazole** | Acute myeloid leukemia/Glioblastoma cancer | Targeting HK2-expressing | 53 |
| **Ketoconazole** | Glioblastoma/Colorectal cancer | Reducing glycolytic metabolism | 54 |
| **Tioconazole** | Breast cancer | Inhibiting ATG4 to suppress autophagy | 55 |
| **Enilconazole** | Colorectal cancer | Inhibiting WNT/β-catenin and PI3K/AKT pathways | 56 |
| **Bedaquiline** | Triple-negative breast cancer | Inhibiting ABCB1 efflux function to reverse MDR | 57,58 |
| **Doxycycline** | Breast cancer | Inhibiting the cancer stem cell phenotype and epithelial-to-mesenchymal transition | 59–61 |
| **Tigecycline** | Ovarian cancer/Myeloid leukemia | Targeting MYC, HIFs, PI3K/AKT or AMPK-mediated mTOR, cytoplasmic P21CIP1/Waf1, and WNT/β-catenin signaling | 62 |
| **Clofocotol** | Prostate cancer | Inhibiting cancer cell growth through activating ER stress and three branches of the UPR pathway | 63 |
| **Ritonavir** | Ovarian cancer/Melanoma | Blocking AKT/mTOR pathway/expressing G1 phase | 64 |
| **Nelfinavir** | Melanoma/Rectal cancer | Suppressing PAX3 and MTIF expression | 65,66 |
| **Maraviroc** | Triple-negative breast cancer | Blocking lymphangiogenesis and cancer metastasis | 67,68 |
| **L-870810** | Cancer | Cytotoxicity in cancer cell and inhibiting select oncogenic kinases | 69 |
| **Aspirin** | Colon cancer/Breast cancer | Inhibiting COX enzymes/downregulating WNT/β-catenin pathway | 70,71 |
| **Celecoxib** | Glioblastoma/Lung cancer | P53-dependent G1 cell cycle arrest and autophagy/downregulating NF-κB, caspase-9, BAX and BCL-XL | 72 |
| **Ibuprofen** | Prostate cancer/Melanoma/Lung cancer/Adenocarcinoma/Gastric cancer | Inhibiting COX enzymes/reducing angiogenesis and cell proliferation/apoptosis | 73,74 |
| **Benzotropine** | Breast cancer/Pancreatic cancer | Acting on SLC6A3/DAT and STAT3 pathways | 75 |
| **Benserazide** | Colon cancer/Melanoma | Inhibiting HK2 pathway | 76 |
| **Donepezil** | Glioblastoma | Increasing cell mitosis and inducing cell mitotic arrest | 77 |
| **Memantine** | Glioblastoma | Inhibiting proliferation/autophagy | 78 |
| **Riluzole** | Hepatocellular carcinoma | Inducing caspase-dependent apoptosis and G2/M cell cycle arrest | 79 |
| **Chlorpromazine** | Glioblastoma/Colorectal cancer | Inhibiting AKT/mTOR pathway | 80 |
| **Fluphenazine** | Triple-negative breast cancer | Inducing G0/G1 cell cycle arrest/apoptosis | 81 |
| Drug                  | Cancer Type/Other Indicated Diseases                                      | Biological Effect                                                                 | Page |
|-----------------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------------|------|
| Penfluridol           | Glioblastoma/Triple-negative breast cancer                                | Inhibiting transcription factor GLI1 and integrin pathway                         | 83   |
| Olanzapine            | Glioblastoma                                                              | Inhibiting proliferation, migration and anchorage-independent growth/inducing apoptosis, necrosis and cytostasis | 84   |
| Risperidone           | Adenocarcinoma                                                            | Decreasing proliferation                                                          | 85   |
| Clomipramine          | Glioblastoma                                                              | Activating JNK/JUN pathway/increasing cytochrome c release and apoptosis activated by caspase-3 | 86   |
| KRICT-9               | Cancer                                                                    | Inhibiting STAT3                                                                  | 47   |
| Imipramine            | Glioblastoma/Small cell lung cancer                                       | Inducing high level of autophagy and cell death                                   | 87   |
| Trimipramine          | Prostate cancer                                                           | Increasing plasma levels of CYP2D6 substrates                                     | 88   |
| Amitriptyline         | Prostate cancer                                                           | Increasing plasma levels of CYP2D6 substrates                                     | 88   |
| All-trans retinoic acid (ATRA) | Colorectal cancer/Acute myeloid leukemia                                  | Enhancing the effects of EVII                                                    | 89   |
| Tranlycypromine       | Breast cancer                                                             | LSD1/HDACs dual inhibitor                                                        | 90   |
| Fluoxetine            | Hepatocellular cancer/Lung cancer                                         | Blocking AKT/NF-κB or ERK/NF-κB activation and inducing apoptosis                 | 91   |
| Citalopram            | Burkitt lymphoma                                                          | Inhibiting proliferation/inducing apoptosis in cancer cell/downregulating AKT pathway | 92   |
| Paroxetine            | Breast cancer                                                             | Inducing apoptosis through Ca2⁺ and P38 MAP kinase-dependent ROS generation      | 93   |
| Sertraline            | Liver cancer/Breast cancer/Prostate cancer                               | Dual activation of apoptosis and autophagy signaling by deregulating redox balance | 94   |
| Proscillaridin A      | Glioblastoma                                                              | Activating GSK3β/alternating microtubule dynamics                                  | 95   |
| Valproic acid         | Prostate cancer/Gastric cancer                                            | Inhibiting histone deacetylase to reduce cancer cell proliferation/apoptosis/inhibiting angiogenesis | 96   |
| Metformin             | Glioblastoma/Non-small cell lung cancer/Rectal cancer/Prostate cancer/Ovarian cancer | Autophagy/apoptosis/inducing G1 cell arrest                                         | 97   |
| Pioglitazone          | Lung cancer/Glioblastoma                                                  | PPARγ/inhibiting WNT/β-catenin pathway/apoptosis                                  | 98,99|
| Repaglinide           | Glioblastoma                                                              | Inhibiting proliferation and migration of tumor cell/reducing BCL-2, Beclin1 and PD-L1 expression/blocking immune checkpoint signaling | 95   |
| Rosiglitazone         | Glioblastoma                                                              | Inhibiting cell proliferation by causing G2/M arrest and apoptosis                 | 100  |
| Buformin              | Breast cancer                                                             | Inhibiting receptor tyrosine kinase (RTK) and mTOR pathway/reducing cell proliferation | 97   |
| Ciglitazone           | Glioblastoma                                                              | Lossing mitochondrial membrane potential along with increasing ROS                 | 98   |
| Phenformin            | Breast cancer/Rectal cancer                                               | Targeting signal transducer and activator of transcription 3 and transforming growth factor-β/Smad signaling | 101  |
| Mebendazole           | Glioblastoma                                                              | Inhibiting proliferation and angiogenesis/BRAF–MEK–ERK pathway/upregulating expression of pro-inflammatory genes | 102  |
| Albendazole           | Lung cancer                                                               | Inhibiting HIF-1α-dependent glycolysis and VEGF                                   | 103  |
| Flubendazole          | Breast cancer                                                             | Inhibiting STAT3 and activating autophagy/targeting P53 and promoting ferroptosis | 104  |
| Niclosamide           | Hepatocellular carcinoma/Adrenocortical carcinoma/Leukemia/Lung cancer/Osteosarcoma | Reversing cancer gene expression/inhibiting tumor cell proliferation              | 105−107|
| Disulfiram            | Glioblastoma                                                              | Activating JNK and P38 pathways/inhibiting NF-κB and MGMT/inducing ROS/DNA damage | 108   |

(continued on next page)
using high-throughput computational docking through molecular fit computations on plenty of FDA-approved drugs and protein structures. Another one is genetic association approaches to identify genes that are associated with a disease, and find potential drug targets of the disease. For instance, genome-wide association studies (GWAS) devote to identify genetic variants associated with common diseases and help identify novel targets for repurposing drug. However, these genes may not be ideal druggable targets. Therefore, pathway mapping could use upstream or downstream genetic, protein or disease data for identifying repurposing targets, and thus greatly improve the identification of drug targets. Recently, a technique termed network-wide association study (NetWAS) can identify disease gene associations much more accurately than GWAS and find more effective targets of anti-hypertensive drugs. To validate the effect of the old drug on cancer, a series of experiments need to be carried out to confirm their therapeutic effects in cancer. Therefore, experimental approaches, such as binding assays and phenotypic screening are indispensable, and can help to identify relevant target interactions in drug repurposing and to identify lead compounds from large compound libraries\(^{15}\). Binding assays can identify target interactions by interaction of ligand and receptor. For example, the cellular thermostability assay (CETSA) technique has been introduced as a way of mapping target engagement in cells using biophysical principles that predict thermal stabilization of target proteins. Phenotypic screening is to identify compounds that show disease-relevant effects in model systems without prior knowledge of the target affected. Typically, \textit{in vitro} phenotypic screening can be carried out by a wide range of cell-based assays in a 96-well format. In the context of drug repurposing, it will screen numerous drugs in several cell lines. For instance, disulfiram, a drug used for alcohol abuse, is identified as a selective antineoplastic agent by high-throughput cell-based screening. With the assistance of these approaches, drug repurposing processes will improve greatly (Fig. 1B). Currently, there are many non-oncology drugs approved by FDA or in clinical trials including cardiovascular drug, antibiotics, antivirals, anti-inflammatory drugs, antipsychotics, and other non-oncology drugs which could be promising candidates for drug repurposing for cancer\(^{16}\).

In this review, we focus on summarizing several repurposing non-oncology small-molecule drugs, as well as highlight their potential targets and molecular mechanisms in cancer therapy.

### 3. Molecular mechanisms repurposing non-oncology drugs in cancer therapy

There are several resources useful for screening non-oncology drug repurposing for cancer therapy. First, drugs that have been withdrawn due to cell toxicity when used for the given indication, but potentially exerting anticancer effects at lower doses. Second, drugs which are already on the market, especially the classic old drugs mentioned above that are used for drug repurposing. Because these drugs have been used in patients for many years, numerous new techniques could be used to find relationships between their original indications and cancer, and finally to identify antitumor effects of these drugs. In addition, compounds which have failed to pass the clinical trial phase could be restudied for their antitumor effects (Fig. 2). All these compounds might acquire or enhance their antitumor effects by structural modification, after which they can go to market for a new indication. All the above approaches provide abundant resources for discovering new
| Drug name | Cancer type                  | Clinical trial identifier |
|-----------|-----------------------------|--------------------------|
| Losartan  | Pancreatic cancer           | NCT03563248 (phase 2)    |
|           |                             | Pancreatic cancer        | NCT01821729 (phase 2) |
|           |                             | Pancreatic cancer        | NCT04106856 (phase 1) |
|           |                             | Osteosarcoma             | NCT03900793 (phase 1) |
|           |                             | Glioblastoma             | NCT03951142 (phase 2) |
| Captopril | Lung cancer                 | NCT00077064 (phase 2)    |
|           | Infantile hemangioma        | NCT04288700 (phase 2)    |
| Verapamil | Brain cancer                | NCT00706810 (phase 2)    |
|           | Hodgkin lymphoma            | NCT03013933 (phase 1)    |
| Carvedilol| Breast cancer               | NCT02993198 (phase 2)    |
|           | Glioblastoma                | NCT03980249 (early phase 1) |
|           | Glioblastoma                | NCT03861598 (early phase 1) |
| Propranolol| Gastric cancer             | NCT04005365 (phase 2)    |
|           | Breast cancer               | NCT02596867 (phase 2)    |
|           | Bladder cancer              | NCT04493489 (phase 2)    |
|           | Pancreatic neoplasms        | NCT03838029 (phase 2)    |
|           | Breast cancer               | NCT02596867 (phase 2)    |
|           | Breast cancer               | NCT02013492 (early phase 1) |
|           | Prostate carcinoma          | NCT03152786 (phase 2)    |
|           | Skin melanoma               | NCT01988831 (phase 2)    |
|           | Esophageal adenocarcinoma   | NCT04682158 (phase 2)    |
|           | Infantile hemangioma        | NCT01056341 (phase 2/3)  |
|           | Cavernous malformations     | NCT03523650 (phase 1)    |
| Atenolol  | Hemangioma                  | NCT02342275 (phase 3)    |
|           | Infantile hemangioma        | NCT03237637 (phase 3)    |
| Digoxin   | Head and neck cancer        | NCT02906800 (phase 1/2)  |
|           | Prostate cancer             | NCT01162135 (phase 2)    |
|           | Malignant melanoma          | NCT01765569 (phase 1)    |
|           | Melanoma                    | NCT02138292 (phase 1)    |
| Pitavastin| Breast cancer               | NCT04705909 (phase 2/3)  |
|           | Acute myeloid leukemia      | NCT04512105 (phase 1)    |
| Simvastatin| Breast cancer              | NCT03324425 (phase 2)    |
|           | Breast cancer               | NCT00334542 (phase 2)    |
|           | Pancreatic cancer           | NCT00944463 (phase 2)    |
|           | Breast cancer               | NCT00807950 (phase 2)    |
|           | Colorectal cancer           | NCT01110785 (phase 2)    |
|           | Adenocarcinoma of rectum    | NCT02161822 (phase 2)    |
|           | Colorectal cancer           | NCT00313859 (phase 2)    |
|           | Myeloma                     | NCT01332617 (phase 2)    |
|           | Multiple myeloma            | NCT00281476 (phase 1/2)  |
|           | Chronic lymphocytic leukemia| NCT00829282 (phase 1)    |
| Atorvastatin| Prostate cancer            | NCT04026230 (phase 3)    |
|           | Prostatic neoplasms         | NCT01821404 (phase 2)    |
|           | Endometrial cancer          | NCT02767362 (early phase 1) |
|           | Malignant disease           | NCT03560882 (phase 1)    |
|           | Kidney cancer               | NCT00490698 (phase 2)    |
|           | Acute myelogenous leukemia  | NCT01491958 (phase 2)    |
|           | Myeloma                     | NCT00164086 (phase 1)    |
|           | Glioblastoma multiforme     | NCT0209573 (phase 2)     |
|           | Hepatocellular carcinoma    | NCT02819869 (phase 2)    |
| Lovastatin| Breast cancer               | NCT00584012 (phase 1)    |
|           | Ovarian cancer              | NCT00585052 (phase 2)    |
|           | Breast cancer               | NCT00285857 (phase 2)    |
|           | Acute myeloid leukemia      | NCT00583102 (phase 1/2)  |
|           | Melanoma                    | NCT00963664 (phase 2)    |
|           | Melanoma                    | NCT00462280 (phase 2)    |
|           | Neurofibromatosis type 1    | NCT00853580 (phase 2)    |
| Verapamil | Brain cancer                | NCT00706810 (phase 2)    |
|           | Recurrent hodgkin lymphoma  | NCT03013933 (phase 1)    |
| Sildenafil| Pancreatic cancer           | NCT02106871 (phase 1)    |
|           | Lung cancer                 | NCT00752115 (phase 2/3)  |
|           | Solid tumor                 | NCT02460802 (phase 1)    |

(continued on next page)
| Drug name                      | Cancer type                             | Clinical trial identifier       |
|--------------------------------|-----------------------------------------|--------------------------------|
| Lymphatic malformations        | NCT02335242 (phase 2)                   |                                |
| Glioblastoma                   | NCT01817751 (phase 2)                   |                                |
| Lymphangioma                   | NCT01290484 (phase 1/2)                 |                                |
| Waldenström’s macroglobulinemia| NCT00165295 (phase 2)                   |                                |
| Chloroquine                    | NCT01575782 (phase 1)                   |                                |
| Breast cancer                  | NCT02333890 (phase 2)                   |                                |
| Lung cancer                    | NCT00969306 (phase 2)                   |                                |
| Breast cancer                  | NCT01446016 (phase 2)                   |                                |
| Malignant neoplasm             | NCT02071537 (phase 1)                   |                                |
| Carcinoma                      | NCT01023477 (phase 1/2)                 |                                |
| Glioma                         | NCT02497641 (phase 1/2)                 |                                |
| Brain metastasis               | NCT01894633 (phase 2)                   |                                |
| Glioblastoma multiforme        | NCT02378532 (phase 1)                   |                                |
| Glioblastoma                   | NCT024532417 (phase 2)                  |                                |
| Glioblastoma multiforme        | NCT00224978 (phase 3)                   |                                |
| Artemisinin                    | NCT04805333 (phase 1)                   |                                |
| Quinacrine                     | NCT00417274 (phase 2)                   |                                |
| Lung cancer                    | NCT01839955 (phase 1)                   |                                |
| Colorectal adenocarcinoma      | NCT01844076 (phase 1/2)                 |                                |
| Renal cell carcinoma           | NCT00574483 (phase 2)                   |                                |
| Itraconazole                   | NCT03513211 (phase 1/2)                 |                                |
| Prostate cancer                | NCT00887458 (phase 2)                   |                                |
| Prostate cancer                | NCT02054793 (phase 1/2)                 |                                |
| Lung cancer                    | NCT03664115 (phase 2)                   |                                |
| Esophageal cancer              | NCT02749513 (early phase 1)             |                                |
| Lung cancer                    | NCT02357836 (early phase 1)             |                                |
| Ovarian cancer                 | NCT03081702 (phase 1/2)                 |                                |
| Lung cancer                    | NCT01900028 (phase 1)                   |                                |
| Prostate cancer                | NCT01450683 (phase 2)                   |                                |

| Drug name                      | Cancer type                             | Clinical trial identifier       |
|--------------------------------|-----------------------------------------|--------------------------------|
| Lung cancer                    | NCT01752023 (phase 2)                   |                                |
| Esophageal neoplasm            | NCT004181100 (phase 2)                  |                                |
| Prostate adenocarcinoma        | NCT01787331 (phase 2)                   |                                |
| Advanced solid tumors          | NCT02259010 (phase 1)                   |                                |
| Ketoconazole                   | NCT00985310 (phase 2)                   |                                |
| Breast cancer                  | NCT00212095 (phase 2)                   |                                |
| Prostate cancer                | NCT0190003859 (phase 2)                 |                                |
| Prostate cancer                | NCT00955376 (phase 1/2)                 |                                |
| Prostate cancer                | NCT000038084 (phase 2)                  |                                |
| Granulosa cell tumour of the   | NCT011584297 (phase 2)                  |                                |
| Advanced cancer                | NCT00708591 (phase 1)                   |                                |
| Prostatic neoplasms            | NCT00032825 (phase 1)                   |                                |
| Breast cancer                  | NCT03796273 (early phase 1)             |                                |
| Solid tumors                   | NCT00697437 (phase 2)                   |                                |
| Ciprofloxacin                  | NCT02252978 (phase 2)                   |                                |
| Bladder cancer                 | NCT00003824 (phase 1)                   |                                |
| Leukemia                       | NCT02773372 (phase 1/2)                 |                                |
| Pancreatic ductal adenocarcinoma| NCT04523987 (phase 1)                  |                                |
| Doxycycline                    | NCT02775695 (phase 2)                   |                                |
| Pancreatic cancer              | NCT02874430 (phase 2)                   |                                |
| Breast cancer                  | NCT01847976 (phase 2)                   |                                |
| Head and neck squamous cell    | NCT03076281 (phase 2)                   |                                |
| Lymphangiomyomatosis           | NCT00989742 (phase 4)                   |                                |
| Cutaneous T-cell lymphoma      | NCT02341209 (phase 2)                   |                                |
| Melanoma                       | NCT01990082 (phase 1/2)                 |                                |
| Ritonavir                      | NCT01009347 (phase 1)                   |                                |
| Nelfinavir                     | NCT02080416 (early phase 1)             |                                |
| Non-hodgkin lymphoma/ Hodgkin  | NCT00704600 (phase 1/2)                 |                                |
| Head and neck neoplasms        | NCT01065844 (phase 2)                   |                                |
| Non-small cell lung cancer     | NCT00791336 (phase 2)                   |                                |
| Non-small cell lung cancer     | NCT01108666 (phase 2)                   |                                |
Table 2 (continued)

| Drug name          | Cancer type                                      | Clinical trial identifier |
|-------------------|--------------------------------------------------|--------------------------|
| Glioblastoma      | NCT00694837 (phase 1)                            |                          |
| Glioma            | NCT01020292 (phase 1)                            |                          |
| Maraviroc         | Hematologic malignancy                          | NCT01785810 (phase 2)    |
|                   | Metastatic colorectal cancer                     | NCT03274804 (phase 1)    |
| Aspirin           | Colorectal cancer                                | NCT00578721 (phase 2)    |
|                   | Colorectal cancer                                | NCT02607072 (phase 3)    |
|                   | Colorectal cancer                                | NCT00565708 (phase 3)    |
|                   | Colorectal cancer                                | NCT02647099 (phase 3)    |
|                   | Colorectal cancer                                | NCT02945033 (phase 3)    |
|                   | Colorectal cancer                                | NCT02965703 (phase 2)    |
|                   | Lynch syndrome                                   | NCT02813824 (phase 3)    |
|                   | Lynch syndrome I                                 | NCT02497820 (phase 3)    |
| Colon cancer/Rectal cancer | NCT00468910 (phase 2)                         |                          |
| Colon cancer      | NCT02301286 (phase 3)                            |                          |
| Colon cancer      | NCT03464305 (phase 3)                            |                          |
| Colon cancer      | NCT00224679 (phase 3)                            |                          |
| Rectal cancer     | NCT03170115 (phase 2)                            |                          |
| Gastric cancer    | NCT04214990 (phase 3)                            |                          |
| Breast cancer     | NCT03491410 (phase 2/3)                          |                          |
| Breast cancer     | NCT07727048 (early phase 1)                      |                          |
| Node positive HER2 negative breast cancer | NCT02927249 (phase 3)                     |                          |
| Fallopian tube cancer | NCT03771651 (early phase 1)                |                          |
| Non-small cell lung cancer | NCT01058902 (phase 3)                       |                          |
| Non-small cell lung cancer | NCT01707823 (early phase 1)               |                          |
| Prostate cancer/Gastro-oesophageal cancer/Colorectal cancer/Breast cancer | NCT02804815 (phase 3) |                          |
| Urinary bladder neoplasms | NCT02350543 (phase 4)                  |                          |

Table 2 (continued)

| Drug name          | Cancer type                                      | Clinical trial identifier |
|-------------------|--------------------------------------------------|--------------------------|
| Esophageal squamous cell carcinoma | NCT03900871 (early phase 1)          |                          |
| Cutaneous melanoma | NCT03396952 (phase 2)                        |                          |
| Nasopharyngeal carcinoma | NCT03290820 (phase 2)         |                          |
| Glioblastoma       | NCT07790452 (phase 2)                         |                          |
| Melanoma           | NCT04062032 (phase 2)                         |                          |
| Melanoma           | NCT04066725 (phase 2)                         |                          |
| Celecoxib          | Endometrium cancer                             | NCT03896113 (phase 2)    |
| Breast cancer      | NCT00328432 (phase 1)                         |                          |
| Breast cancer      | NCT01695226 (phase 2)                         |                          |
| Breast cancer      | NCT000056082 (phase 2)                        |                          |
| Breast cancer      | NCT00045591 (phase 2)                         |                          |
| Breast cancer      | NCT00291694 (phase 2)                         |                          |
| Breast cancer      | NCT02429427 (phase 2)                         |                          |
| Metastatic cancer  | NCT03864575 (phase 2)                         |                          |
| Oral squamous cell carcinoma | NCT02739204 (phase 2)         |                          |
| Lung cancer        | NCT00104767 (phase 1)                         |                          |
| Lung cancer        | NCT01503385 (phase 2)                         |                          |
| Lung cancer        | NCT00020878 (phase 2)                         |                          |
| Prostate cancer    | NCT02840162 (phase 2)                         |                          |
| Prostate cancer    | NCT00022399 (phase 2)                         |                          |
| Prostate cancer    | NCT00073970 (phase 2)                         |                          |
| Prostate cancer    | NCT00136487 (phase 2/3)                       |                          |
| Recurrent respiratory papillomatosis | NCT00571701 (phase 2) |                          |
| Cervix neoplasms   | NCT005152828 (phase 1/2)                      |                          |
| Head and neck cancer/Lung cancer | NCT00527982 (phase 2) |                          |
| Non muscle invasive bladder cancer | NCT02343614 (phase 2) |                          |
| Head and neck cancer | NCT00061906 (phase 2) |                          |
| Head and neck cancer | NCT00014404 (phase 2) |                          |
| Smoldering multiple myeloma | NCT00099047 (phase 2) |                          |
| Recurrent bladder cancer | NCT0006124 (phase 2/3) |                          |
| Uterine cancer     | NCT00233829 (phase 2)                         |                          |

(continued on next page)
**Table 2 (continued)**

| Drug name | Cancer type | Clinical trial identifier |
|-----------|-------------|--------------------------|
| Colorectal carcinoma | NCT00582660 (phase 2) |  |
| Cervical carcinoma | NCT00081263 (phase 2) |  |
| Non-small cell lung cancer | NCT01018186 (phase 1) |  |
| Lymphangioleiomyomatosis | NCT02484664 (phase 2) |  |
| Memantine | Glioblastoma | NCT01260467 (phase 2) |
| Chlorpromazine | Glioblastoma multiforme/ MGMT-unmethylated glioblastoma | NCT04224441 (phase 2) |
| Fluphenazine | Multiple myeloma and plasma cell neoplasm/ Multiple myeloma | NCT00335647 (phase 1/2) |
| Imipramine | Breast cancer | NCT01322444 (early phase 1) |
| Metformin | Breast cancer | NCT010302002 (early phase 1) |
| | Breast cancer | NCT04387630 (phase 2/3) |
| | Breast cancer | NCT01266486 (phase 2) |
| | Breast cancer | NCT01310231 (phase 2) |
| | Breast cancer | NCT01589367 (phase 2) |
| | Breast cancer | NCT01566799 (phase 2) |
| | Breast cancer | NCT00930579 (phase 2) |
| | Breast cancer | NCT00909506 (phase 2) |
| | Prostate cancer | NCT03137186 (phase 2) |
| | Prostate cancer | NCT01620593 (phase 2) |
| | Prostate cancer | NCT01243385 (phase 2) |
| | Prostate cancer | NCT01215032 (phase 2) |
| | Prostate cancer | NCT01677897 (phase 2) |
| | Prostate cancer | NCT01733836 (phase 2) |
| | Prostate cancer | NCT04925063 (phase 2) |
| | Prostate cancer | NCT00881725 (phase 2) |
| | Prostate cancer | NCT01864096 (phase 3) |
| | Prostate cancer | NCT03031821 (phase 3) |
| | Endometrial cancer | NCT01205672 (early phase 1) |
| | Endometrial cancer | NCT01911247 (early phase 1) |
| | Endometrial cancer | NCT02990728 (phase 2) |
| | Endometrial cancer | NCT02042495 (phase 2) |
| | Endometrial cancer | NCT00582660 (phase 2) |
| | Endometrial cancer | NCT01632020 (phase 2) |
| | Endometrial cancer | NCT01926769 (phase 2) |
| | Colon cancer | NCT01440127 (phase 1) |
| | Rectal cancer | NCT02437656 (phase 2) |
| | Bladder cancer | NCT03379909 (phase 2) |
| | Head and neck cancer | NCT02402348 (early phase 1) |
| | | Head and neck squamous cell cancer |
| | | Non-small cell lung cancer |
| | | Non-small cell lung cancer/ Lung cancer |
| | | Non-small cell lung cancer/ Lung cancer |
| | | Well-differentiated neuroendocrine tumors |
| | | Hepatocellular carcinoma |
| | | Chronic lymphocytic leukemia |
| | | Lung cancer |
| | | Thyroid cancer |
| | | Non-small cell lung cancer |
| | | Non-small cell lung cancer |
| | | Pancreatic cancer |
| | | Pancreatic cancer |
| | | Prostate cancer |
| | | Skin squamous cell cancer |
| | | Medulloblastoma/ Astrocytoma/Glioblastoma/ Anaplastic astrocytoma/Brain stem neoplasms/ Oligodendroblastoma/ Anaplastic oligodendroglioma/ Malignant glioma |
| | | High-grade glioma |
| | | Colon cancer |
| | | Colorectal cancer |
| | | Metastatic breast cancer |
| | | Melanoma |
| | | Endometrial cancer |
anticancer drugs. Repurposing old drugs for antitumor therapy is an effective and economical way to develop new anticancer drugs. According to their original indications, we summarized these repurposing non-oncology small-molecule drugs for cancer therapy (Table 1).

3.1. Cardiovascular drugs repurposing for cancer therapy

Several experimental studies have demonstrated that drugs approved by FDA, which are commonly prescribed for the treatment or prevention of cardiovascular diseases, have promising anticancer properties. Some analyses of retrospective clinical data suggest that the use of cardiovascular drugs to treat hypertension in cancer patients is likely to extend survival of patients with pancreatic and other cancers. Some of these drugs have advanced to randomized clinical trials (RCTs) to confirm their antitumor effects (Table 2, sourced by http://clinicaltrials.gov).

For example, losartan (Fig. 3, 1) is a cardiovascular agent affecting the renin-angiotensin system (RAS), which is also a potential target for modulating tumor-infiltrating immune cells. In tumors, it could act on RAS to decompress vessels by reducing solid stress to improve vessel density and decrease vessel diameter and eventually normalize the tumor microenvironment. Subsequently, it was found that losartan depletes the matrix via inducing antifibrotic miRNAs including miR-133 and miR-29, which can reduce collagen I levels in cancer cells to modulate solid stress. Additionally, losartan reduced cell proliferation and tumor growth as well as inducing apoptosis. In a phase II clinical trial of losartan, patients with previously untreated unresectable pancreatic tumor showed downstaging of locally advanced pancreatic ductal adenocarcinoma and a higher success rate on subsequent surgical resection. This suggests that losartan may be worth studying as a drug active for pancreatic cancer. Similarly, irbesartan (Fig. 3, 2), valsartan (Fig. 3, 3), telmisartan (Fig. 3, 4) and olmesartan (Fig. 3, 5) also mediate anticancer effects via a mechanism like that of losartan. Captopril (Fig. 3, 6) also exerts effect on RAS and shows efficacy for inhibiting colorectal liver metastases by significantly decreasing tumor viability and impairing metastatic growth. It modulates the spatial and temporal infiltration of CD3⁺ CD4⁺ lymphocytes into the tumor, and the activation of T cell subtypes in the tumor and liver tissues. Enalapril (Fig. 3, 7), verapamil (Fig. 3, 8) and benazepril (Fig. 3, 9) are also reported to show effects on cancer.

Another cardiovascular drug carvedilol (Fig. 3, 10) affects β-adrenoreceptor for treatment of hypertension, and its potential ability to resistance to skin cancer caused by sun exposure was serendipitously revealed as a result of an experimental error, a new finding first published in 2017. However, it is little known about how carvedilol affects cancer-related outcomes. To explain this, it was discovered that carvedilol blocks the effects of sympathetic nervous system activation through β-adrenoreceptor signaling and metastasis and invasion of breast cancer were blocked in a mouse model. Additionally, carvedilol induced mitochondrial damage including mitochondrial swelling, crista damage and formation of myelin figures, and inhibited growth factor receptors to mediate anti-proliferative and anti-migratory effects in cancer cells.

**Figure 3**  Chemical structures of 1–16 as cardiovascular drugs for repurposing in cancer therapy.
and increase survival in experimental animal models of pancreas cancer. In clinical trials, carvedilol is often combined with imatinib to enhance in vitro anticancer activity in glioma or with trastuzumab to prevent and alleviate drug-related cardiotoxicity in breast cancer. These results suggest that β-blockers could represent novel drugs to treat cancer progression. Propranolol (Fig. 3, 11) is a non-selective β-adrenoreceptor blocker used to treat arrhythmia, but it also exerts effect on melanoma by inhibiting angiogenesis and disrupting migration of cancer cells via inhibition of noradrenaline-dependent responses. Propranolol is the first line therapy for infantile hemangioma, acting by interference with SOX18 transcriptional activity to inhibit angiogenesis. Atenolol (Fig. 3, 12) acts in the same manner as propranolol to inhibit apoptosis, proliferation, migration, and inflammatory cell responses for cancer therapy. These drugs are new attractive, inexpensive, and relatively safe therapeutics for cancers. Cardiac glycosides (CGs) such as digoxin (Fig. 3, 13) and digitoxin are compounds found in natural sources that are used to treat different cardiac conditions. The antitumor effects of CG were suggested in 1979 in a study of chemotherapy for breast cancer treated in combination with digoxin. It was used to treat cardiovascular disease by inhibiting the Na+/K+-ATPase which results in an elevation of the intracellular Na+ level in cardiomyocytes, such that the Na+/Ca2+ exchanger mechanism is stimulated. This results in increased intracellular Ca2+ concentration, prompting myocardial contractility. However, CGs can also bind to Na+/K+-ATPase in cancer cells and disrupt it, causing apoptosis. In addition, CGs could treat cancer via other targets. The eukaryotic translation initiation factor 4F complex (eIF4F) which regulates the translational initiation has been recognized as a potential chemotherapeutic target in triple-negative breast cancer (TNBC). CGs could treat TNBC as an inhibitor of eIF4F which is modulated by c-MYC levels. c-MYC can be phosphorylated through the RAS-ERK pathway, and CGs may also be related to the reduction of hypoxia-induced activation of the ERK pathway. CGs also induce the expression of P21Cip1, an inhibitor of cyclin-dependent kinases, resulting in growth arrest. In addition, CGs can affect TRAIL-mediated apoptosis and suppress HIF-1α accumulation for cancer therapy. Therefore, CGs are a broad category of compounds derived from natural products which show potential anticancer effects by targeting multiple pathways. Statins are common cholesterol-lowering prescription drugs which inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), a rate-limiting enzyme of the mevalonate pathway, thus decreasing cholesterol biosynthesis. Recently, it was discovered that the mevalonate pathway coincides with some cancer pathway, and thus, that cholesterol-lowering drugs may also be used in cancer therapy. For example, pitavastatin (Fig. 3, 14), which is the most promising of these for repurposing as an antitumor drug, can induce death in almost half of neoplastic cells but with much lower mortality in normal cells. Its antitumor mechanism is related to the mevalonate pathway and macrophagocytosis. Mevalonate pathway provides geranylgeranyl pyrophosphate (GGPP) which cancer cells depend for macrophagocytosis nutrient uptake. Statins selectively inhibit the mevalonate pathway, which eventually leads to amino acid starvation and subsequent cell death due to the depletion of GGPP. Pitavastatin also shows anticancer activity through inducing autophagic death by inhibiting NF-κB, suppressing tumor cell MDR-1 protein and inhibiting cell proliferation. In addition, other statins like simvastatin (Fig. 3, 15), mevastatin (Fig. 3, 16) and fluvastatin (Fig. 4, 17) can suppress the PI3K/AKT and RAS/ERK pathways to inhibit cancer. Atorvastatin (Fig. 4, 18) down-regulates expression of membrane type 1 MMP via the P38 MAPK pathway. Lovastatin (Fig. 4, 19) may inhibit G0/G1 cell cycle transition to prevent cell proliferation and activate LKB1-AMPK-P38MAPK-P53-survivin cascade to cause MCF-7 cell death. Cerivastatin (Fig. 4, 20) downregulates FAK phosphorylation to inhibit cell adhesion and invasion. Statins were found to regulate cell proliferation, apoptosis, and tumor progression in cancer patients, and could reduce cancer induction and improve survival.
In addition, ticlopidine (Fig. 4, 21) also shows antitumor efficacy via inducing cell autophagy by coordinately elevating the level of cAMP41. Prazosin (Fig. 4, 22) has been found to have off-target activity to inhibit glioblastoma growth via the PKCδ-dependent inhibition of the AKT pathway, which results in caspase-3 activation42. Fenofibrate (Fig. 4, 23) can be developed for chemoprevention or treatment of colon cancer by activating peroxisome proliferators-activated receptors-α (PPAR-α) which regulates the occurrence of colon cancer associated with DNMT1-mediated methylation of P21 and PRMT6-mediated methylation of P2743. Verapamil (Fig. 4, 24) and sildenafil (Fig. 4, 25) are also reported to effect on cancer127,128.

These drugs were initially found to have antitumor effect via their original target, but some of them have multiple targets for cancer treatment. Therefore, other new targets are likely to be found by studying and seeking the repurposing of cardiovascular drugs. Thus, cardiovascular drugs represent a broad category of drugs for repurposing for cancer therapy by several pathways. The first step of drug repurposing is to find its effective target for cancer, whereby some drugs have the same antitumor target as in their original indications. In fact, the potential of cardiovascular drugs in oncology remains clinically untapped because most available clinical data originate from retrospective studies and small prospective studies that are potentially biased. Therefore, more effort could be exerted in this area of repurposing drugs for tumor treatment.

3.2. Microbiological agents repurposing for cancer therapy

Microbiological agents are mainly used for treating malaria, fungal and bacterial infections. Some of these drugs have shown promising anticancer activity and entered phase II/III clinical trials.

3.2.1. Anti-malaria drugs

Chloroquine (Fig. 5, 26) and its derivatives hydroxychloroquine (Fig. 5, 27) and mefloquine (Fig. 5, 28) are used for the prevention and treatment of malaria and have shown promising results in...
combination with other anticancer drugs. A key target is the inhibition of autophagy by preventing lysosomal acidification or lysosome fusion through targeting AMPK pathway. NF-κB and P53 also inhibit tumor cell proliferation and growth by autophagy in cancer cells. In a phase I/II trial of everolimus and hydroxychloroquine in patients, decreased cytotoxicity when mTOR inhibitors are combined with an autophagy inhibitor was observed. For autophagy in stromal cells, chloroquine or their derivatives could be promising antineoplastic agents in the next decades.

Artemisinin (Fig. 5, 29) and its derivatives dihydroartemisinin (Fig. 5, 30), artesunate (Fig. 5, 31), artether (Fig. 5, 32), arteether (Fig. 5, 33) have also shown selective anticancer properties in phase I/II trials via their cytotoxic effects. It was found that artemisinin could induce caspase-dependent apoptosis by the intrinsic mitochondrial pathway, regulated by antiapoptotic proteins like BCL-2, and pro-apoptotic factors like BID and BAK in cancer cells. Additionally, artemisinin exhibits immunomodulation in cancer by inhibiting T-cell activation and proliferation and inhibiting signal transducer and activator of transcription (STAT3), cancer metastasis and resistance to chemotherapy and sensitize cancer cells to chemotherapy. However, the use of artemisinin has unexpected resulting in hepatotoxicity, thus, its repurposing for cancer therapy must be approached with caution. Daraprim (Fig. 5, 34) is another anti-malaria drug which also targets STAT3 to treat cancer. Quinacrine (Fig. 5, 35) and amodiaquine (Fig. 5, 36) have been found to kill tumors by induction of apoptosis and autophagy. These drugs similarly target cell autophagy or apoptosis via several pathways to treat cancer. Some of these drugs like artemisinin, which is derived from the extracted ingredients of traditional Chinese medicine to treat malaria worldwide, show effects on cancer therapy. Artemisinin derivatives with structure modification could have enhanced anticancer effects. For example, one synthetic derivative, OZ439 (artefenomel) (Fig. 5, 37), shows effective and promising alternative cancer therapeutic effects by stabilizing the peroxide pharmacophore. Therefore, natural products of traditional Chinese medicine are also a new way to explore effective anticancer drugs.

3.2.2. Anti-fungal drugs

Some azole anti-fungal agents approved by the FDA also show antitumor effects, for example, itraconazole was recently identified as a promising anticancer chemotherapeutic through high-throughput screens. Itraconazole (Fig. 6, 38) exerts its antifungal effects through potent inhibition of CYP51, while its side chain region may inhibit the hedgehog (Hh) signaling pathway which is a signaling cascade responsible for cell proliferation, differentiation, and tissue growth in embryogenesis. In addition, itraconazole can induce cholesterol redistribution to trigger autophagy via inhibition of the AKT-mTOR signaling pathway, finally inhibiting cell proliferation. Posaconazole (Fig. 6, 39) is a derivative of itraconazole that exerts antitumor effects by targeting hexokinase2 (HK2) to regulate tumor growth, invasion, and angiogenesis. Ketoconazole (Fig. 6, 40) was the first oral active azole antifungal agent synthesized in 1976 but it was withdrawn from the European market in 2013 because of its severe hepatotoxic adverse reactions. It also has anticancer effects by targeting the HK2 pathway and exacerbating mitophagy to induce apoptosis by downregulating cyclooxygenase-2 (COX2) in hepatocellular carcinoma. Tioconazole (Fig. 6, 41) shows anticancer effect by enhancing chemotherapeutic drug-induced cytotoxicity in cancer cells and suppressing autophagy by inhibiting ATG4 to regulate tumor growth, metastasis and resistance to chemotherapy and sensitize cancer cells to chemotherapy. Enilconazole (Fig. 6, 42) can target the WNT/β-catenin/TCF signaling pathway to inhibit cancer cell migration and growth. These anti-fungal agents originally targeted fungal pathogens, but are also found to treat cancer in vivo. Their therapeutic targets in humans are also like other drugs like those targeting the WNT, PI3K/AKT/mTOR and ROS pathways.

3.2.3. Synthetic anti-bacterial drugs

Ciprofloxacin (Fig. 6, 43) belongs to the second generation of synthetic quinolone anti-bacterial agent with a broad spectrum of anti-bacterial activity. ATP-binding cassette subfamily B member 1 (ABCB1) is one of the major drug efflux transporters that is known to cause multidrug resistance (MDR) in cancer patients. Ciprofloxacin can reverse MDR by inhibiting the ABCB1 efflux function. In addition, ciprofloxacin can promote cell apoptosis and regulate the function of immune cells for cancer treatment. According to research, ciprofloxacin is able to promote the production of interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) and the polarization of CD86+CD206+ macrophages, while inhibiting the polarization of CD86+CD206- macrophages which plays an important role in tumor regulation. Ciprofloxacin may

![Figure 7 Chemical structures of 44–47 as antibiotics for repurposing in cancer therapy.](Image)
inhibit liver cancer by upregulating the expression of CD86⁺CD206⁺ macrophages. Thus, ciprofloxacin has a potential to be developed as a combination anticancer therapy. Microbiological agents are promising candidates for drug repurposing for cancer therapy, but further clinical development and research are required to translate these findings into clinical applications.

3.3. Antibiotics repurposing for cancer therapy

Antibiotics are used to treat bacterial infection, but they are also being studied for their ability to target cancer cells. Those exhibiting antitumor activity including β-lactams, tetracyclines and anti-tuberculosis drugs. Bedaquiline (Fig. 7, 44) is an FDA-approved antibiotic that is used to treat multi-drug resistant pulmonary tuberculosis (TB) by inhibiting the bacterial ATP-synthase. Due to eukaryotic mitochondria originally evolving from engulfed aerobic bacteria, it is reasonable to hypothesize that bedaquiline might target the mitochondrial ATP-synthase and lead to mitochondrial dysfunction and ATP depletion in cancer cells. In fact, bedaquiline was found to inhibit mitochondrial oxygen consumption, glycolysis in MCF7 breast cancer cells and block the propagation and expansion in MCF7-derived stem-like cancer cells (CSCs). Mitochondria play an important role in cancer treatment and offer potential applications for mtDNA modifications as novel anticancer targets. Therefore, bedaquiline could be a promising chemotherapeutic for cancer, but further preclinical studies and human clinical trials in cancer patients are needed to confirm this.

Tetracyclines drugs like doxycycline (Fig. 7, 45) and tigecycline (Fig. 7, 46) could target oxidative mitochondrial metabolism to prevent the propagation of cancer. They could induce cell cycle arrest, apoptosis, autophagy, and oxidative stress in cancer, and inhibit cell proliferation, migration, invasion, and angiogenesis through targeting PI3K/AKT, AMPK-mediated mTOR, cytoplasmic P21, and WNT/β-catenin signaling.

Clofoctol (Fig. 7, 47) was used for the treatment of upper respiratory tract infections in France and Italy by alteration of bacterial membrane permeability owing to its hydrophobic nature. Now, it has been reported that clofoctol can inhibit protein translation in mammalian cells, so it could serve as a potential anticancer drug. Clofoctol could inhibit cancer cell growth through activation of the unfolded protein response (UPR) pathway in the endoplasmic reticulum (ER), which is a major cellular organelle for folding and maturation of secretory proteins. If misfolded proteins accumulate over the limit of the capacity of ER-associated degradation, the UPR pathway will be activated by one of three sensing proteins, either IRE1, PERK or ATF6, to improve the protein folding and down-regulate protein translation in the ER to reduce the ER folding load. There is already evidence suggesting that many types of cancer cells have higher levels of ER stress, so the UPR pathways are already active to maintain cellular homeostasis. Therefore, further increasing the ER stress could result in overload of the stress responses in cancer cells and in turn induce cell cycle arrest or cell death. Clofoctol induces ER stress and activates all three UPR pathways in PC3 cells, thus inhibiting protein translation and inducing G1 phase cell cycle arrest. Antibiotics are attractive compounds for their ability to target cancer cells and inhibit bacterial infection. The repurposing of antibiotics to treat human tumors is based on a reasonable hypothesis that they target a new mechanism, namely, eukaryotic mitochondria originally evolved from engulfed aerobic bacteria. In these studies, antibiotics show promising antitumor effect and will be worthwhile to make expand efforts.

3.4. Antiviral drugs repurposing for cancer therapy

Antiviral drugs are used to treat a group of viruses inducing serious diseases. Apart from the human immune deficiency virus (HIV), most viral diseases are self-limiting illnesses. For example, ritonavir (Fig. 8, 48) shows a potential use for ovarian cancer, glioblastoma, and lung cancer with additive effects in conjunction with conventional chemotherapeutic regimens. Ritonavir was found to exert antitumor effects by inducing cell cycle arrest with decreasing expression of G1 phase cyclins and cyclin dependent kinases (CDKs), and by promoting apoptosis by increasing the expression of BAK and inhibiting BCL-2. Ritonavir was found to exert antitumor effects by inducing cell cycle arrest with decreasing expression of G1 phase cyclins and cyclin dependent kinases (CDKs), and by promoting apoptosis by increasing the expression of BAK and inhibiting BCL-2. Ritonavir was found to exert antitumor effects by inducing cell cycle arrest with decreasing expression of G1 phase cyclins and cyclin dependent kinases (CDKs), and by promoting apoptosis by increasing the expression of BAK and inhibiting BCL-2.

Figure 8 Chemical structures of 48–51 as antiviral drugs for repurposing in cancer therapy.
for cancer therapy. Nelfinavir (Fig. 8, 49) can improve current approaches of targeted melanoma therapy. MAPK-pathway inhibitors (MAPKi) are usually used for treating melanoma, pancreatic cancer, and rectal cancer, but long-term BRAF and MEK inhibition will induce drug resistance in melanoma. It has been found that the acquired resistance is induced by the upregulation of the melanoma survival oncogene MITF which is regulated by PAX3. Nelfinavir can decrease MAPKi-induced drug tolerance by suppressing PAX3 and MITF expression in BRAF mutant melanomas. The PAX3–MITF axis is a good target for MITF-driven drug tolerance and the expression of PAX3 is tightly regulated by BRAF-initiated MAPK signaling through SMAD2/4 and the SKI complex which is controlled by transforming growth factor b (TGF-b). Therefore, targeting SMAD2/4 and the SKI complex to keep them in a steady-state condition is correlated with a reduction in PAX3 and MITF expression.

In clinical research, combination therapy of nelfinavir with short course hypofractionated radiotherapy (SCHRT) increases tumor perfusion and radiosensitizes tumors in rectal cancer.

Maraviroc (Fig. 8, 50) is another antiviral drug repurposed for triple-negative breast cancer (TNBC) therapy which acts as a C-C chemokine receptor 5 (CCR5) inhibitor to block lymphangiogenesis and lung metastasis. It has been shown that interleukin-6 (IL-6) and C-C chemokine ligand 5 (CCL5) play important roles in TNBC tumor growth and metastasis. Therefore, targeting CCR5, which is widely expressed on tumors, is a new therapeutic target for metastatic TNBC tumor growth and metastasis. Thus, maraviroc could be repurposed for cancer treatment. In one study, a combination of tocilizumab and maraviroc decreased cellular viability, and a combination of maraviroc and cMKR1-1 resulted in greater inhibition of tumor growth compared to each single agent. Compounds with structure modifications might have enhanced antitumor effects as well. For example, 8-hydroxy-1,6-naphthyridines (L-870810) (Fig. 8, 51) is one of a promising class of antitumor drugs developed by Merck Laboratories. Optimization of L-870810 shows significant cytotoxicity in a panel of cancer cell lines and effectively inhibits select oncogenic kinases. Therefore, it is possible to apply it to cancer therapy, but this requires more verification. Antiviral drugs may reveal antitumor activity by examining clinical data retrospectively and finding decreased incidence rates, for example, of HIV-related cancers after taking antiviral drugs. These clinical data suggest that antiviral drugs have potential to treat cancer.

3.5. Anti-inflammatory drugs repurposing for cancer therapy

Anti-inflammatory drugs have anticancer effects because inflammation can also induce cancer. They mainly exhibit anticancer activity through inhibition of cyclooxygenase (COX) enzymes. For example, aspirin (Fig. 9, 52) is commonly used for the treatment and prevention of atherosclerotic disease. In 1988, it was first shown to reduce the risk of colorectal cancer in a clinical trial. Since then, several studies have been demonstrated that aspirin can reduce the incidence of several different cancers. The anti-neoplastic effects of aspirin have been attributed to its inhibition of COX-1 and COX-2 enzymes which promote carcinogenesis through synthesis of PGE2. PGE2 effects are mediated by E-prostanoid (EP) receptor signaling impacting on G-protein coupled receptors to promote proliferation, invasion, secretion of angiogenic factors and inhibition of apoptosis. In one study, knocking out the gene for COX-2 or any of several PGE2 receptor genes resulted in decreased intestinal tumor incidence in mouse models of colorectal cancer (CRC). In addition, phosphatidylinositol 3-kinase (PI3K) and WNT/β-catenin/TCF signaling pathways play a major role for aspirin inhibition of carcinogenesis. The WNT/β-catenin/TCF signaling pathway is activated by extracellular WNT ligand binding to surface receptors, followed by β-catenin translocating to the nucleus and binding to TCF and finally affecting cell proliferation and migration. TCF activity is related to the transcription of a TCF-responsive reporter gene and the WNT/TCF transcriptional target CYCLIN D1. Aspirin can attenuate TCF-responsive reporter gene activity and downregulate CYCLIN D1 by modulating TCF activity. In clinical trials, aspirin could enhance the anticancer effects in non-small cell lung cancer by targeting GRP78 activity, and therefore it could be a potential drug for novel anticancer treatments.

Auranofin (AUR) (Fig. 9, 53) is a FDA-approved anti-rheumatoid arthritis (anti-RA) drug. Recently, it was reported that AUR potently upregulates hepcidin expression and induces ferroptosis both in vitro and in vivo, which is related to some diseases. Its canonical signaling pathways to regulate iron, including the BMP/SMAD and IL-6/JAK/STAT3 pathways, play indispensable roles in mediating AUR’s effects. Interestingly, AUR also exerts an effect on glioblastoma multiforme by inhibiting cathepsin B expression, which may inhibit glioblastoma growth, and by inhibiting thioredoxin reductase (TXNRD) activity, thus increasing intracellular ROS and resulting in cell death. However, AUR shows only moderate activity as a single agent in clinical applications in cancer treatment. Celecoxib (CE) (Fig. 9, 54) was unexpectedly identified as potently enhancing the anticancer activity of AUR in vitro and in vivo through a high-throughput screening of the FDA-approved drug library. The AF/CE combination induces severe oxidative stress that causes ROS-mediated inhibition of hexokinase (HK) and a disturbance of mitochondrial redox homeostasis, resulting in a significant decrease of ATP generation in tumors. According to one study, CE promotes ROS generation by disrupting the mitochondrial respiration chain, but the exact targets of celecoxib in the mitochondria remain unclear. It was reported that CE could reduce cell viability by induction of DNA damage, leading to P53-dependent...
G1 cell cycle arrest and P53-dependent autophagy by down-regulation of NF-κB, caspase-9, BAX and BCL-XL.

Ibuprofen (Fig. 9, 55) has a long history in research seeking new anticancer agents. Previously, S ibuprofen was found to have anti-inflammatory effects, while the R form is inactive, but it could mediate anticancer effects in humans by converting R ibuprofen into S ibuprofen. A recent study by the National Institutes of Health (INSA) found that ibuprofen has an anticancer effect on colon cancer and inhibits malignant cell growth. In their research, ibuprofen’s anticancer mechanism is to prevent cancer cells from producing tumorigenic variants of certain proteins. Additionally, a combination of ibuprofen and celecoxib showed effects on cancer in the liver of Walker-256 tumor-bearing rats by increasing the expression of genes associated with fatty acid oxidation (PPARα and CPT1) and consequently the production of ATP to normalize the energy status. Tumors are caused by repeated stimulation of inflammation, and therefore chronic inflammation is often followed by neoplasia and inflammatory cells are also present in tumor tissues as well. Some inflammatory factors can increase the invasive ability of malignant tumor cells. Thus, inflammation is inextricably linked to tumorigenesis, and anti-inflammatory drugs could represent a resource for discovering antitumor drugs.

3.6. Anti-neurodegenerative drugs repurposing for cancer therapy

Neurodegenerative diseases result from the loss of neurons or their myelin sheaths. Commonly seen disease mainly including Parkinson’s disease, Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The endogenous cholinergic system plays a key role in neuronal cells by suppressing neurite outgrowth and myelination and is found to favor tumor growth in some cancer cells. Drugs for treating neurodegenerative diseases have been found to have antitumor effects as well. For example, benztropine (Fig. 10, 56) is currently a second-line drug for the treatment of Parkinson’s disease, but has been discovered to possess anticancer activity by a tumor spheroid-based multiplex phenotypic screening system. It was found to be an effective compound for inhibition of in vitro tumor spheroid formation and cancer cell survival. Benztropine could suppress tumor growth, reduce circulating tumor cells and metastasis by acting on SLC6A3/DAT and reducing STAT3. In addition, matrix metalloproteinases (MMP), especially MMP9, are often highly expressed in human cancers and are related to the poor prognosis of patients. In further studies, MMPs were found to enhance tumor progression. The promoters of MMPs contain binding sites for oncogenic transcription factors like STAT, NF-κB and the TCF/β-catenin complex. Benztropine can suppress MMP expression by regulating these transcription factors to inhibit cancer cell invasiveness. Additionally, benserazide (Fig. 10, 57) was reported to suppress tumor growth by inhibiting HK2 which plays a vital role in tumor initiation and maintenance. In addition, benserazide could reduce glucose uptake, lactate production and intracellular ATP levels, and cause cell apoptosis and increased loss of mitochondrial membrane potential as well.

Donepezil (Fig. 10, 58) is used for Alzheimer’s disease, but it also shows antitumor activity by increasing cell mitosis duration or inducing cell mitosis arrest. Memantine (Fig. 10, 59) also shows to be effective on cancer through inhibition of proliferation and induction of autophagy mediated by NMDAR1. Riluzole (Fig. 10, 60) is an amyotrophic lateral sclerosis (ALS) drug, the action of which was also investigated on hepatocellular carcinoma, where it was found to suppress cell proliferation in liver cells.
cancer and to induce the caspase-dependent apoptosis pathway and G2/M cell cycle arrest\(^\text{60}\). In addition, a new antitumor target pathway for nilotinib is to inhibit the release of cellular glutamate, which decreases the production of cellular GSH and increases the production of ROS, which in turn results in cell death as well. Neurodegenerative diseases are characterized by deposits of misfolded proteins in the brain, and one treatment approach is to regulate them by inhibiting poly ADP-ribose polymerase (PARP), which is also a target of cancer treatment. Therefore, anti-neurodegenerative drugs could be studied for treating cancer as well. However, more detailed research is necessary for drug repurposing to utilize anti-neurodegenerative drugs to treat cancer.

### 3.7. Antipsychotic drugs repurposing for cancer therapy

Antipsychotic drugs are commonly prescribed for the treatment of psychosis, schizophrenia, bipolar disorder, and other diseases, but many studies have indicated that some of these drugs may also mediate antitumor activity. In the 1950's, chlorpromazine (CPZ) (Fig. 11, 61), the first drug to treat psychosis, was found by accident in clinical trials, which has opened a new era of modern psychotropic drug therapy. According to the structure and pharmacological mechanisms of action, antipsychotics can be divided into first and second generation drugs\(^\text{62}\). CPZ, belonging to the phenothiazine class of anti-psychotic drugs, was a first-generation anti-psychotic used in the late sixties and early seventies as the most important drug for schizophrenia and psychotic disorders. In the meantime, CPZ has been identified as a potential candidate for drug repurposing in cancer. It was found that it exerted antitumor effects linked to the inhibition of cancer cell growth and proliferation by regulating the expression of related proteins and interfering with mitochondrial processes. In glioma cell lines, CPZ exerts its anti-proliferative effect by inducing autophagic cell death through inhibition of the PI3K/AKT/mTOR pathway. In addition, CPZ can increase the expression of the cyclin-dependent kinase (CDK) inhibitor P21, which thus causes cell cycle arrest in the G2/M-phase. In colorectal cancer cells, CPZ induces apoptosis via up-regulation of P53. Additionally, CPZ inhibits the mitotic kinesin KSP/Eg-5, resulting in mitotic arrest and cell cycle inhibition\(^\text{63}\).

Fluphenazine hydrochloride (Flu; Fig. 11, 62) is another commonly prescribed antipsychotic drug. In one study, Flu showed potential for the treatment of TNBC and its brain metastases by inducing G0/G1 cell cycle arrest and promoting mitochondria-mediated intrinsic apoptosis in vitro. Moreover, Flu could suppress the growth and proliferation of breast cancer cells by decreasing the expression of p44/42 ERK and phosphorylated AKT, which are two key molecules in RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways in both TNBC cell lines. In addition, Flu could induce G0/G1 phase arrest in TNBC cells through downregulation of expression of CDK2, CDK4 and CYCLIN D1 and up-regulation of P21 and P27\(^\text{64}\). According to one study, Flu might induce apoptosis via the mitochondria-mediated intrinsic apoptotic pathway and suppress TNBC cell migration and invasion in vitro. Penfluridol (PF) (Fig. 11, 63) also shows to exert antitumor effects in vivo by suppressing tumor growth via AKT-mediated inhibition of the transcription factor GLI1. In glioma cells, PF treatment could reduce cancer cell migration and invasion by decreasing integrin a6 and uPAR levels, which was mediated by downstream activation of FAK, paxillin, RAC, and ROCK proteins. In breast cancer cell lines, PF treatment inhibited the expression and activation of these downstream proteins. Integrins are an important therapeutic target in various cancer types related to cancer cell metastasis. Hence, reducing integrin expression might suppress the expression of the epithelial-to-mesenchymal transition (EMT) factors, vimentin and Zeb1 to inhibit the cancer metastasis. Furthermore, a combination of PF and temozolomide (TMZ) significantly suppressed tumor growth and prolonged survival in vivo\(^\text{65}\).

Olanzapine (Fig. 11, 64) is a second-generation anti-psychotic drug mainly used in clinical treatment. It can inhibit cancer cell proliferation, migration, and anchorage-independent growth and induce apoptosis, necrosis and cytostasis in tumor cells. It also disrupts cholesterol homeostasis to kill cancer cells\(^\text{66}\). Similarly, risperidone (Fig. 11, 65) also shows promise as a potential adeno-carcinoma treatment by slowing proliferation of PC3 prostate cancer cells\(^\text{67}\). Clozapine (Fig. 11, 66) is repurposed for cancer therapy by activating phosphorylation of c-JUN and increasing cytochrome c release and caspase-3-like activation, thus leading to apoptosis of cancer cells\(^\text{68}\). SH-1-14 (Fig. 11, 67) and KRITC-9 (Fig. 11, 68) are used to treat dementia, but also have new indications for cancer by inhibiting STAT3\(^\text{69}\). Antipsychotic drugs are an important group for repurposing and show promising anticancer effects. Hence, more research is justified to identify their mechanism of action.

### 3.8. Antidepressants repurposing for cancer therapy

Antidepressants are a group of psychotropic drugs used primarily for the treatment of psychiatric disorders characterized by mood depression. Antidepressants were first introduced in the 1950s, and mainly used to treat depression and various depressive states. Notably, several studies have reported that antidepressants may have antitumor activity. For example, tricyclic antidepressants (TCAs) are the most common first-generation antidepressants containing three fused rings in their structure. Imipramine (Fig. 12, 69) exerts effects on cancers such as glioma, small cell lung cancer (SCLC) and others\(^\text{70}\). Imipramine induces cell autophagy and cell death by inhibiting P2RY12\(^\text{41}\). Trimipramine (Fig. 12, 70) and amitryptiline (Fig. 12, 71) are also used to treat cancer\(^\text{71}\). Recently, it has been reported that combining an antidepressant and a drug derived from vitamin A is a promising way to treat leukemia. All-trans retinoic acid (ATRA) (Fig. 12, 72) has been successfully used to treat acute myeloid leukemia (AML), but it is not effective for other common types of AMLs\(^\text{72}\). Tranylcypromine (Fig. 12, 73) could also exert effects on AMLs by inducing the leukemic cells to mature and die naturally. Selective serotonin reuptake inhibitors (SSRIs) are a new class of antidepressants which were first tested in clinical trials in the 1980s. They reduce cell proliferation and induce apoptosis in cancer cells and downregulate pAKT to mediate the synergistic anti-proliferative interactions with other chemotherapeutic drugs\(^\text{73}\). For example, fluoxetine (Fig. 12, 74) induces autophagic cell death via eEF2K—AMPK–mTOR—ULK pathway in triple negative breast cancer\(^\text{74}\). Citalopram (Fig. 12, 75), paroxetine (Fig. 12, 76) and sertraline (Fig. 12, 77) are all SSRIs and show anticancer activity as well\(^\text{75,76,77}\). Proscillaridin A (ProA) (Fig. 12, 78) exerts antitumor effects through GSK3β activation in WNT pathway and alteration of microtubule dynamics in glioblastoma\(^\text{78}\). Valproic acid (VPA; Fig. 12, 79) inhibits histone deacetylase to reduce cancer cell proliferation and induce apoptosis, as well as inducing differentiation and inhibiting angiogenesis in cancer\(^\text{79}\). Antidepressants mainly inhibit reuptake of amine neurotransmitters, but their antitumor mechanism are
Figure 12  Chemical structures of 69−79 as antidepressants for repurposing in cancer therapy.

Figure 13  Chemical structures of 80−97 as other drugs for repurposing in cancer therapy.
more complicated, and more effort should be required for drug repurposing.

3.9. Other drugs repurposing for cancer therapy

3.9.1. Antidiabetics

In addition to the above drugs, there are many others that could be repurposed for cancer as well. For example, some of the drugs for type II diabetes show anti-neoplastic effects. Metformin (Fig. 13, 80) is a classic drug for diabetes, and shows effects on several cancers like glioblastoma multiforme, non-small cell lung cancer, rectal cancer, prostate cancer, and ovarian cancer. It might be able to treat cancer by inducing autophagy, apoptosis, and cell death via activating AMPK. In addition, it downregulates the AKT–mTOR signaling pathway and inhibits CLIC1 activity to induce G1 cell arrest. Pioglitazone (Fig. 13, 81) is also an anti-diabetes drug that might be used to treat lung cancer by its highly selectivity for peroxisome proliferator-activated receptor gamma (PPARγ). It can inhibit β-catenin expression to block the WNT signal pathway and reduce cell viability and proliferation, and induce apoptosis. Regaplinide (Fig. 13, 82), rosiglitazone (Fig. 13, 83), buformin (Fig. 13, 84), cigitazone (Fig. 13, 85) and phenformin (Fig. 13, 86) all have anti-hyperglycemic effects and show anticanic activity.

3.9.2. Anthelminthic drugs

Anthelminthic drugs are also a class of repurposed drugs for cancer treatment. For example, mebendazole (Fig. 13, 87) inhibits proliferation of cancer cell by inducing tubulin depolymerization resulting in mitotic arrest. It leads to P53 accumulation and cell cycle arrest in the G2/M phase, consequently inducing cell apoptosis mediated by cytochrome c, caspase-9, and caspase-3. Additionally, it inhibits TNK, which is an activator of the WNT/TCF/β-catenin transcriptional program. Inhibition of the BRAF–MEK–ERK signal pathway, which is related to cell growth, proliferation, and survival, is another target of this drug. Mebendazole also upregulates the expression of pro-inflammatory genes to reduce levels of VEGF and VCAM-1 and eventually inhibit tumor growth. Albendazole (Fig. 13, 88) is also repurposed for antitumor treatment to target the altered redox status of cancer cells, which is an interesting approach for new cancer therapy. It promotes the generation of ROS, thereby oxidizing DNA at C4 of deoxyribose causing DNA breakage and triggering apoptosis as well as inducing cell death by increasing P53 and BAX expression, at the same time as diminishing BCL-XL expression. Albendazole activity appears to be related to tubulin polymerization inhibition which is responsible for separation of duplicated chromosomes during cell division, thereby promoting cell cycle arrest at the G2/M phase. Albendazole (Fig. 13, 89) can target ATG4B in breast cancer to induce cell autophagy. Additionally, it was found to up-regulate the expression of EVA1A, which is related to cell autophagy and apoptosis in triple-negative breast cancer. Niclosamide (Fig. 13, 90) is an anti-parasitic drug showing antitumor activity in hepatocellular carcinoma through reversing the HCC gene expression signature, based on computational modeling of public data. In this way, niclosamide and its ethanolamine salt was discovered to bind to the cell division cycle 37 (CDC37) protein and disrupt its interaction with heat shock protein 90 (HSP90) to inhibit tumor cell proliferation. Simultaneously, it also reduces the expression of proteins in the WNT/β-catenin, STAT3, AKT–mTOR, EGFR–RAS–RAF signaling pathways, which are fundamental to HCC development.

3.9.3. Other drugs

Disulfiram (Fig. 13, 91) is used for treating alcoholism but may be repurposed to treat glioma, NSCLC, CRC, and esophageal squamous cell carcinoma. The molecular anticancer target of disulfiram is an adaptor of the human ubiquitin selective protein segregease P97, which plays a role in the turnover of proteins orchestrating stress-related signaling pathways. AM404 (Fig. 13, 92) is a metabolite of acetaminophen with antibacterial activity, and has been validated as an inducer of cell differentiation and inhibitor of neoplastic cell growth in both in vitro and ex vivo models. It exerts anticancer activity by suppressing oncogenic FBXL5 in colorectal cancer cells to regulate the PTEN/P53/AKT signal pathway and HIF-1 transcriptional activity which then results in colon cancer death. To further confirm this result, AM404 is sensitive to FBXL5-knockout cells and causes further additive effects by inhibiting cell migration. Salbutamol (Fig. 13, 93) is used for bronchial asthma, but is found also to affect cancer by activating the β2 adrenergoreceptor. Raloxifene (Fig. 13, 94) and bazedoxifene (Fig. 13, 95) are also used to treat osteoporosis with potential usefulness for cancer therapy by inhibiting IL-6/GP130 interactions in redirection studies. Cationic amphiphilic anti-histamines have been studied for their anticancer actions as well; they were found to induce lysosomal membrane permeabilization and cell death preferentially in cancer cells. Thiabendazole (Fig. 13, 96) might be a potential new chemotherapeutic for cancer by disrupting vascular networks.

More recently, immunotherapy has been the hot topic of cancer treatment and some old drugs have also been repurposed for potential cancer immunotherapy by targeting PD-1/PD-L1, CD47, and TIGIT/PVR. For instance, niclosamide can enhance the cancer cell lysis mediated by T cells in the presence of PD-L1 blockade and delayed the tumor growth and increase the survival which is associated with the increase of tumor infiltrating T cells and granzyme B release. It suggests that the combination therapy of niclosamide and PD-1/PD-L1 blockade is worth to be further studied in clinic. In addition, azelnidipine (Fig. 13, 97), an anti-hypertensive drug approved by the FDA, can be repositioned for cancer immunotherapy by dual blocking CD47/SIRPα and TIGIT/PVR pathways by co-targeting SIRPα and PVR. In vivo, azelnidipine alone or combined with irradiation can significantly inhibit the growth of MC38 tumors and CT26 tumors by enhancing the infiltration and function of CD8+ T cell in tumor. As mentioned above, an increasing number of drugs have been repurposed for cancer immunotherapy, indicating a promising potential on cancer therapy.

4. Concluding remarks and future perspectives

Drug repurposing is becoming an attractive therapeutic strategy for exploiting more approved non-oncology drugs to improve potential cancer therapy, which, in turn provides a new avenue for discovery of candidate small-molecule compounds for cancer drug development. It is well-known that discovery of novel antitumor agents is costly and time-consuming; therefore, new strategies for drug repurposing may drastically reduce the research and
development cycle because of their safety, toxicity, and pharmacological properties. Accordingly, many FDA-approved drugs or experimental drugs used for treating other diseases can be reused for exploring their potential antitumor effects. Repurposed drugs can be further investigated according to their off-target effects, which might be inversely related to their therapeutic target in cancer. Based on the retrospective clinical data, prior knowledge of the side effects of old drugs may have a huge therapeutic potential on different types of human cancers. Interestingly, some of these old drugs have the same target that is related to the occurrence of two or more different diseases; therefore, a drug which retains its original indication can also be used to treat human cancers.

Presently, a set of new technologies has been emerging for drug repurposing, which would help identifying novel druggable targets for old therapeutic agents. For instance, large-scale multi-omics sequencing containing genomics, proteomics, transcriptomics and phenomics can help understand disease mechanism, elucidate drug mechanism of actions and identify new use of old drugs. Usually, multi-omics is an approach to identify the drug—disease relationships by comparing drug gene expression profiles and disease gene expression profiles with the help of CMap, a key source of data to construct a detailed map for functional associations among diseases, genetic perturbations, and drug actions. For example, antidepressant drugs have been identified for the treatment of small cell lung cancer by using multi-omics sequencing. Another approach is to discover small-molecule drugs that provoke similar transcriptional responses for they can share similar mode of action in one disease. In addition, multi-omics sequencing analyzes gene expression profiles of cancer cells and identify a few of mutated cancer genes that are associated with drug sensitivity may serve as potential biomarkers of drug response by using hundreds of clinical or preclinical drugs for large-scale screening of human cancer cell lines. In addition, genome-wide positioning systems network (GPSnet) algorithms can be used to identify the similarity between drug targets and disease proteins in human protein—protein interaction (PPI) groups, which may be conducive to determining repurposed drug action targets. With the increasing focus on drug repurposing, there have accumulated a plenty of information about these researches than ever before, therefore it is difficult for scientists to process data and find useful information by themselves. But data processing advances have made a rapid progress in artificial intelligence (AI), which has been also used in drug repurposing by outsource our reasoning to a machine intelligence when it comes to the analysis of multisource and multidimensional data. Applying a particular AI algorithm in drug repurposing is a sequential process that requires the proper definition of the problem domain. Thus, the first step is to constructing a model which ensures the choice of the machine learning method appropriate for the problem under study. Once the model and the data sets have been established, one may proceed to model training and evaluation. For example, machine learning models implementing AI methods have been successfully applied in several aspects of the virtual screening including structure-based virtual screening (SBVS) and ligand-based virtual screening (LBVS). These approaches greatly improve the drug repurposing process and decrease the cost of drug discovery. Additionally, combinations of multi-omics and AI approaches can be used to clarify the key signaling pathways of cancer progression and metastasis, and further identify druggable targets and relevant mechanisms. They can be applied for modeling biological processes to identify new disease-relevant targets and drug phenotype associations. For example, structure-based virtual screening methods have greatly decreased the costs of drug redirecting processes. Also, molecular docking and ligand-based chemoinformatics can be used to elucidate new drug—target interactions. More importantly, CRISPR/Cas9 genome editing technology has been developing into a robust tool for identifying drug targets for future cancer therapy by knock-down and knock-out specific genes in cancer cells. High-throughput screening on cell phenotype can be used to discover systematic target—phenotype relationship by screening thousands of compounds in numerous types of cancer cells.

In conclusion, we summarized about 100 small-molecule non-oncology drugs with therapeutic potential, including cardiovascular drugs, microbiological drugs, small-molecule antibiotics, anti-viral drugs, anti-inflammatory drugs, anti-neurodegenerative drugs, antipsychotic drugs, antidepressants, and other drugs in cancer. Moreover, we discussed their potential targets and relevant key pathways for cancer treatment. Although the current success rate of drug reuse is low, it is a promising avenue for discovery of small-molecule drugs for fighting human cancers. With the development of newer biological, chemical, and computational technologies, the bottleneck of drug repurposing should be ultimately overcome; thereby providing a new perspective from old non-oncology drugs to new anticancer agents in the future.
3. Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. *JAMA Intern Med* 2017;177:1569–75.

4. Kaushik I, Ramachandran S, Prasad S, Srivastava SK. Drug rechanneling: a novel paradigm for cancer treatment. *Semin Cancer Biol* 2021;68:279–90.

5. Aggarwal S, Verma SS, Aggarwal S, Gupta SC. Drug repurposing for breast cancer therapy: old weapon for new battle. *Semin Cancer Biol* 2021;68:8–20.

6. Basso J, Miranda A, Sousa J, Pais A, Vitorino C. Repurposing drugs for glioblastoma: from bench to bedside. *Cancer Lett* 2018;428:173–83.

7. Sanz MA, Fenaux P, Tallman MS, Estey EH, Lowenberg B, Naeo T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. *Biol Blood Marrow Transplant* 2019;133:1630–43.

8. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. *Blood* 2017;129:1275–83.

9. Dimopoulos MA, Kastritis E. Thalidomide for myeloma: still here?. *Protein Cell* 2021;12:128–44.

10. Wang C, Zhang T, Liao Q, Dai M, Guo J, Yang X, et al. Metformin inhibits prostate cancer progression by targeting tumor-associated inflammatory infiltration. *Clin Cancer Res* 2018;24:5622–34.

11. Wang C, Zhang T, Liao Q, Dai M, Guo J, Yang X, et al. Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation. *KRAS4B: a novel therapeutic target in pancreatic cancer side population cells. *Int J Oncol* 2016;49:99–110.

12. Yao H, Jiang L, Lin X, Liang ZG. Fluvasatin combined with benazepril may contribute to the favorable prognosis of patients with atrial fibrillation. *Biomed Pharmacother* 2016;83:687–92.

13. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cells. *Int J Oncol* 2016;49:99–110.

14. Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, et al. Fluvastatin potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins. *Cell Death Dis* 2020;11:477.

15. Fengrich V, Chen NM, Neef M, Waldmann J, Buchholz M, Feldmann G, et al. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. *Gut* 2010;59:630–7.

16. Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cells. *Int J Oncol* 2016;49:99–110.

17. Yao H, Jiang L, Lin X, Liang ZG. Fluvasatin combined with benazepril may contribute to the favorable prognosis of patients with atrial fibrillation. *Biomed Pharmacother* 2016;83:687–92.

18. Gillis RD, Botteri E, Chang A, Ziegler AL, Chung NC, Pon CK, et al. Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients. *Eur J Cancer* 2021;147:106–16.

19. Parteeke LI, Speerfork S, Kading A, Seubert F, Kuhn S, Lorenz E, et al. Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade. *Prenat Diagn* 2016;36:823–33.

20. De Giorgi V, Gazzini M, Benemini S, Marchionni N, Botteri E, Pencacciohi E, et al. Propranolol for off-label treatment of patients with melanoma: results from a cohort study. *JAMA Oncol* 2018;4:e172908.

21. Overman J, Fontaine F, Wylie-Sears J, Moustaqil M, Huang L, Meurer M, et al. R-Propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma. *Elife* 2019;8:e43026.

22. Regulski K, Regulski M, Karolak B, Murias M, Stanis B. Can cardiovascular drugs support cancer treatment? The rationale for drug repurposing. *Drug Discov Today* 2019;24:1059–65.

23. Platiz EA, Yegnasubramanian S, Liu JO, Chong CR, Shin JS, Kenfield SA, et al. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. *Cancer Discov* 2011;1:68–77.

24. Howard CM, Estrada M, Terrero D, Tiwari AK, Raman D. Identification of cardiac glycosides as novel inhibitors of gefitinib-mediated translation in triple-negative breast cancer cells. *Cancers (Basel)* 2020;12:2169.

25. Ma L, Meng Y, Tu C, Cao X, Wang H, Li Y, et al. A cardiac glycoside HTF-1 isolated from *Helleborus thibetanus* Franch displays potent in vitro anti-cancer activity via caspase-9, MAPK and PI3K-Akt-mTOR pathways. *Eur J Med Chem* 2018;158:34:1270–7.

26. Sibulkin DA, Frangioni JV, Zhu XP. Angiotensin inhibition enhances drug delivery and potentiates antitumor efficacy in a breast cancer model. *Ann Oncol* 2016;27:2040–46.

27. Christophi C, et al. Immunomodulatory effects of renin–angiotensin system inhibitors on T lymphocytes in mice with colorectal liver metastases. *Cell Mol Med* 2013;17:687–94.

28. Jones MR, Schrader KA, Shen Y, Pleasure E, Ch’ng C, Dar N, et al. Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer. *Ann Oncol* 2016;27:801–6.

29. Lin YT, Wang HC, Tsai MH, Su YY, Yang MY, Chien CY. Angiotensin II receptor blockers valsartan and losartan improve survival rate clinically and suppress tumor growth via apoaptosis related to caspase-9, MAPK and PI3K-Akt-mTOR pathways. *Eur J Med Chem* 2018;158:743–52.

30. Pani S, Picardi P, Ciaglia E, D’Alessandro A, Bifulco M. Novel prospects of statins as therapeutic agents in cancer. *Pharmacol Res* 2014;88:84–98.

31. Jiao Z, Cai H, Long Y, Sirka OK, Padmanaban V, Ewald AJ, et al. Statin-induced GGBP depletion blocks macrophage activation and starves cells with oncocogenic defects. *Proc Natl Acad Sci U S A* 2020;117:4158–68.

32. Yin L, He Z, Yi B, Xue L, Sun J. Simvastatin suppresses human breast cancer cell invasion by decreasing the expression of pituitary tumor-transforming Gene 1. *Front Pharmacol* 2020;11:574068.

33. Okubo K, Isomo M, Miyai K, Asano T, Sato A. Fluvastatin potentiates anticancer activity of vinorelbine in renal cancer cells. *Cancer Sci* 2020;111:112–26.

34. Jones HM, Fang Z, Sun W, Clark LH, Stine JE, Tran AQ, et al. Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro. *Am J Cancer Res* 2017;7:2478–90.

35. Huang SW, Chyuon IT, Shuie C, Yu MC, Hsu YF, Hsu MJ. Lovastatin-mediated MCF-7 cancer cell death involves LKB1–AMPK–p38MAPK–p33–survivin signalling cascade. *J Cell Mol Med* 2020;24:1822–36.

36. Shichors K, Massaras A, Hanahan D. Dual targeting of the autophagic regulatory circuitry in gliomas with repurposed drugs elicits cell-
lethal autophagy and therapeutic benefit. Cancer Cell 2015;28: 456–71.

42. Assad Kahn S, Costa SL, Gholamin S, Nitta RT, Dubois LG, Fev M, et al. The anti-hypertensive drug prazosin inhibits glioblastoma growth via the PKCdelta-dependent inhibition of the AKT pathway. EMBO Mol Med 2016;8:511–26.

43. Luo Y, Xie C, Brocker CN, Fan J, Wu X, Feng L, et al. Intestinal PPARAlphaprotects against colon carcinogenesis via regulation of methyltransferases DNMT1 and PRMT6. Gastroenterology 2019; 157:744–759 e4.

44. Varisi L, Cen O, Vlahopoulos S. Dissecting pharmacological effects of chloroquine in cancer treatment: interference with inflammatory signaling pathways. Immuno lology 2020;159:257–78.

45. Qin G, Zhao C, Zhang L, Liu H, Quan Y, Chai L, et al. Dihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cells. Apoptosis 2015;20:1072–86.

46. Wong YK, Xu C, Kalesh KA, He Y, Lin Q, Wong WSF, et al. Artemisinin as an anticancer drug: recent advances in target profiling and mechanisms of action. Med Res Rev 2017;37:1492–517.

47. Thilakasiri PS, Dmello RS, Nero TL, Parker MW, Ernst M, Chandel AL. Repurposing of drugs as STAT3 inhibitors for cancer therapy. Semin Cancer Biol 2021;68:31–46.

48. Oien DB, Pathoulas CL, Ray U, Thirusangu P, Kalogera E, Gozari M, Alborz M, El-Seedi HR, Jassbi AR. Chemistry, biosynthesis, and mechanisms of action. Cancer Res 2013;73:163–70.

49. Chen ZS. Ciprofloxacin enhances the chemosensitivity of cancer through global inverse gene-expression profiling. Theranostics 2018;8:744.

50. Qin G, Zhao C, Zhang L, Liu H, Quan Y, Chai L, et al. Dihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cells. Apoptosis 2015;20:1072–86.

51. Antonarakis ES, Heath EI, Smith DC, Rathkopf D, Blackford AL, Danila DC, et al. Repurposing iraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Onco l 2013;18:163–73.

52. Liu R, Li J, Zhang T, Zou L, Chen Y, Wang K, et al. Itraconazole suppresses the growth of glioblastoma through induction of autophagy: involvement of abnormal cholesterol trafficking. Autophagy 2014;10:1241–55.

53. Aghiothi S, Mansouri S, Burrell K, Li M, Mamatjan Y, Liu J, et al. Ketogenic and posaconazole selectively target HK2-expressing glioblastoma cells. Clin Cancer Res 2019;25:844–55.

54. Chen Y, Chen HK, Wang K, Zhang L, Huang Z, Liu J, et al. Ketone bodies enhance the mitochondria to induce apoptosis by down-regulating cyclooxygenase-2 in hepatocellular carcinoma. J Hepatol 2019;70:66–77.

55. Liu PF, Tsai KL, Hsu CJ, Tsai WL, Cheng JS, Chang HW, et al. Drug repurposing screening identifies tococonanol as an ATG4 inhibitor that suppresses autophagy and sensitizes cancer cells to chemotherapy. Theranostics 2018;8:330–45.

56. van Noort V, Scholth S, Iskar M, Zeller G, Ostertag K, Schweitzer C, et al. Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-expression profiling. Cancer Res 2014;74:5600–9.

57. Gupta P, Gao HL, Ashar YV, Karadhkelhar NM, Yogananth S, Chen ZS. Ciprofloxacin enhances the chemosensitivity of cancer cells to ABCB1 substrates. Int J Mol Sci 2019;20:268.

58. Fan M, Chen S, Weng Y, Li X, Jiang Y, Wang X, et al. Ciprofloxacin promotes polarization of CD86 ‘CD206’ macrophages to suppress liver cancer. Oncol Rep 2020;44:91–102.

59. Tiberi S, du Plessis N, Walz G, Vjceja MJ, Rao M, Ntoumi F, et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis 2018;18:e183–98.

60. Fiorillo M, Lamb R, Tanowitz HB, Cappello AR, Martinez-Outschoorn UE, Sotgia F, et al. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs). Aging (Albany NY) 2018;6:1593–607.

61. Chen K, Lu P, Beeraka NM, Sukocheva OA, Madhunapantula SV, Liu J, et al. Mitochondrial mutations and mitochondrial dysfunction: focus on regulation of oxidative stress-induced responses in breast cancers. Semin Cancer Biol 2020. Available from: https://doi.org/10.1016/j.semcancer.2020.09.012.

62. Dong Z, Abbas MN, Kausar S, Yang J, Li L, Tan L, et al. Biological functions and molecular mechanisms of antibiotic tigecycline in the treatment of cancers. Int J Mol Sci 2019;20:3577.

63. Wang M, Shin JS, Li RJ, Dang Y, He Q, Das M, et al. Identification of an old antibiotic clofotecol as a novel activator of unfolded protein response pathways and an inhibitor of prostate cancer. Br J Phar macol 2014;171:4478–89.

64. Kumar S, Bryant CS, Chamala S, Qazi A, Seward S, Pal J, et al. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells. Mol Cancer 2009;8:26.

65. Smith MP, Brunt SN, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, et al. Inhibiting drivers of non-mutational drug tolerance is a salvage strategy for targeted melanoma therapy. Cancer Cell 2016;29:270–84.

66. Meyn RE, Krishnan S, Skinner HD. Everything old is new: using nelfinavir to radiosensitize rectal cancer. Clin Cancer Res 2016;22:1834–6.

67. Xiao J, Nawab O, Patel T, Kossenkov AV, Halama N, Jaeger D, et al. Recent advances targeting CCR5 for cancer and its role in immune-oncology. Cancer Res 2019;79:4801–7.

68. Jin K, Pandey NB, Popel AS. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis. Breast Cancer Res 2018;20:54.

69. Zeng LF, Wang Y, Kazemi R, Xu S, Xu ZL, Sanchez TW, et al. Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties. J Med Chem 2012;55:9492–509.

70. Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer 2016;16:173–86.

71. Kmitowicz Z. Study finds possible role for aspirin as treatment for colon cancer. BMJ 2012;344:e2298.

72. Han Y, Chen P, Zhang Y, Lu W, Ding W, Luo Y, et al. Synergy between auranofin and celecoxib against colon cancer in vitro and in vivo through a novel redox-mediated mechanism. Cancers (Basel) 2019;11:931.

73. Yang L, Wang H, Yang X, Wu Q, An P, Jin X, et al. Auranofin mitigates systemic iron overload and induces ferroptosis via distinct mechanisms. Signal Transduct Target Ther 2020;5:138.

74. Zuo C, Hong Y, Qiu X, Yang D, Liu N, Sheng X, et al. Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3/β-catenin and L1CAM activities. Cancers (Basel) 2020;12:523.

75. de Souza CO, Kurauchi MA, Silva Fde F, de Morais H, Curi R, Hirabara SM, et al. Celecoxib and ibuprofen restore the ATP content and the gluconeogenesis activity in the liver of walker-256 tumour-bearing rats. Cell Physiol Biochem 2015;36:1659–69.

76. Sugawa C, Eguchi T, Tran MT, Ishige M, Trin K, Okusha Y, et al. Antiparkinson drug benztropine suppresses tumor growth, circulating tumor cells, and metastasis by acting on SLC6A3/DAT and reducing ferritin in vitro. Cancer Res 2016;76:2680–90.

77. Priyanka HP, Singh RV, Mishra M, Thyagrajan S. Diverse age-related effects of Bacopa monnieri and donepezil in vitro on cytokine production, antioxidant enzyme activities, and intracellular targets in splenocytes of F344 male rats. Int Immunopharmac 2013;15:260–74.
97. Kreuzwitzer D, Tawfic QA. Expanding role of NMDA receptor antagonists in the management of pain. CNS Drugs 2019;33:347–74.
98. Seol HS, Lee SE, Song JS, Lee HY, Park S, Kim I, et al. Glutamate release inhibitor, riluzole, inhibited proliferation of human hepatocellular carcinoma cells by elevated ROS production. Cancer Lett 2016;382:157–65.
99. Abbruzzese C, Matteoni S, Persico M, Villani V, Paggi MG. Repurposing chlorpromazine in the treatment of glioblastoma multiforme: analysis of literature and forthcoming steps. J Exp Clin Cancer Res 2020;39:26.
100. Xu F, Xia Y, Feng Z, Lin W, Xue Q, Jiang J, et al. Repositioning antipsychotic fluphenazine hydrochloride for treating triple negative breast cancer with brain metastases and lung metastases. Am J Cancer Res 2019;9:459–78.
101. Kim H, Chong K, Ryu BK, Park KJ, Yu MO, Lee J, et al. Repurposing pentfluoridol in combination with temozolomide for the treatment of glioblastoma. Cancers (Basel) 2019;11:1310.
102. Wiklund ED, Catts VS, Catts SV, Ng TF, Whitaker NJ, Brown AJ, et al. Cytotoxic effects of antipsychotic drugs implicate cholesterol homeostasis as a novel chemotherapeutic target. Int J Cancer 2010;126:28–40.
103. Dilly SJ, Clark AJ, Marsh A, Mitchell DA, Cain R, Fishwick CWG, et al. A chemical genomics approach to drug reprofiling in oncology: antipsychotic drug risperidone as a potential adrenocortical treatment. Cancer Lett 2017;393:16–21.
104. Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Muller DJ, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPCi) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 2017;102:37–44.
105. Wang J, Byers LA. Teaching an old dog new tricks: drug repurposing and inhalation of repurposed drugs. J Cancers (Basel) 2019;10:2822–36.
106. Lu L, Dong J, Wang L, Xia Q, Zhang D, Kim H, et al. Activation of STAT3 and Bel-2 and reduction of reactive oxygen species (ROS) promote radioreistance in breast cancer and overcome of radioresistance with niclosamide. Oncogene 2018;37:5292–304.
107. Luo F, Luo M, Rong QX, Zhang H, Chen Z, Wang F, et al. Niclosamide, an anthelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. J Immunother Cancer 2019;7:245.
108. Siegelin MD, Schneider E, Westhoff MA, Wirtz CR, Karpel-Massler G. Current state and future perspective of drug repurposing in malignant glioma. Semin Cancer Biol 2021;68:92–104.
109. Ahmed M, Jinks N, Babaei-Jaddid R, Kashfi H, Castellanos-Uribe M, May ST, et al. Repurposing antibacterial AM404 as a potential anticancer drug for targeting colorectal cancer stem-like cells. Cancers (Basel) 2019;12:106.
110. Kim JH, Lee J, Park KS, Hong SW, Gho YS. Drug repositioning to alleviate systemic inflammatory response syndrome caused by Gram-negative bacterial outer membrane vesicles. Adv Healthc Mater 2018;7:e1701476.
111. Li H, Xiao H, Lin L, Jou D, Kumari V, Lin J, et al. Drug design targeting protein–protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/CP130 interface. J Med Chem 2014;57:632–41.
112. Ellegaard AM, Dehleroff C, Vind AC, Anand A, Cederkvist L, Petersen NHT, et al. Repurposing cationic amphiphilic antisthama lignes for cancer treatment. ElBioMedicine 2016;9:130–9.
113. Cha HJ, Byrom M, Mead PE, Ellington AD, Wallingford JB, Marcotte EM. Evolutionarily repurposed networks reveal the well-known antifungal drug thalidomide to be a novel vascular disrupting agent. PLoS Biol 2012;10:e1001379.
114. Zhou X, Jiao L, Qian Y, Dong Q, Sun Y, Zheng WV, et al. Repositioning azelnidipine as a dual inhibitor targeting CD47/SIRPalpha and TIGIT/PVR agonists in vitro and in mice by inhibiting cell division cycle 37 signaling. Adv Healthc Mater 2018;7:e1701476.
115. Ishida J, Konishi M, Ebner N, Springer J. Repurposing of approved drugs for drug repositioning in oncology: an extensive review of current literature. Cancers (Basel) 2019;11:1284.
116. Castro LS, Kvicieinskas MR, Ouirque F, Parisotto EB, Grinevicius VM, Correia JF, et al. Albendazole as a promising molecule for tumor control. Redox Biol 2016;10:90–9.
117. Zhang L, Guo M, Li J, Zheng Y, Zhang S, Xie T, et al. Systems biology-based discovery of a potential Agt4B agonist (thalidomide) that induces autophagy in breast cancer. Mol Biosyst 2015;11:2860–6.
followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. *JAMA Oncol* 2019;5:1020–7.

117. Huang KM, Liang S, Yeung S, Oiyemhonlan E, Cleveland KH, Parsa C, et al. Topically applied carvedilol attenuates solar ultraviolet radiation induced skin carcinogenesis. *Cancer Prev Res (Phila)* 2017;10:598–606.

118. Kim J, Grotegut CA, Wisler JW, Mao L, Rosenberg PB, Rockman HA, et al. The beta-arrestin-biased beta-adrenergic receptor blocker carvedilol enhances skeletal muscle contractility. *Proc Natl Acad Sci U S A* 2020;117:12435–43.

119. Eguven M, Yazihan N, Aktas E, Sabanci A, Li CJ, Oktem G, et al. Carvedilol in glioma treatment alone and with imatinib in vitro. *Int J Oncol* 2010;36:857–66.

120. Guglin M, Krischer J, Tamura R, Fink A, Bello-Matriscia L, McCaskill-Stevens W, et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. *J Am Coll Cardiol* 2019;73:2859–68.

121. Fumagalli C, Maurizi N, Marchionni N, Fornasari D. Beta-blockers: their new life from hypertension to cancer and migraine. *PharmacoRes* 2020;151:104587.

122. Karasneh RA, Murray LJ, Cardwell CR. Cardiac glycosides and breast cancer risk: a systematic review and meta-analysis of observational studies. *Int J Cancer* 2017;140:1035–41.

123. Kaushik V, Azad N, Yakisich JS, Iyer AK. Antitumor effects of docetaxel in advanced prostate cancer by stimulating NO. *Biochim Biophys Acta Rev Cancer* 2017;1871:e1434–54.

124. Dinic J, Efferth T, Garcia-Sosa AT, Grahovac J, Padron JM, Pajeva I, et al. Repurposing old drugs to fight multidrug resistant cancers. *Drug Resist Updates* 2020;36:100713.

125. Cheng F, Lu W, Liu C, Fang J, Hou Y, Handy DE, et al. A genome-wide positioning of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma. *Clin Cancer Res* 2019;25:2080–7.

126. Haas NB, Appleman LJ, Stein M, Redlinger M, Wilks M, Xu X, et al. Autophagy inhibition to augment mTOR inhibition: a phase II/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma. *Clin Cancer Res* 2019;25:2080–7.

127. Efferth T. From ancient herb to modern drug: *Artemisia annua* and artemisinin for cancer therapy. *Semin Cancer Biol* 2017;46:65–83.

128. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. High-dose citalopram and escitalopram and the risk of out-of-hospital death. *J Clin Psychol* 2017;73:1890–9.

129. Rauschenbach L, Wieland A, Reinartz R, Kebir S, Till A, Darkwa Oppong M, et al. Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma. *Eur J Cancer* 2020;140:130–9.

130. Marima R, Hull R, Dlaminzi Z, Penny C. Efavirenz and lopinavir/ritonavir alter cell cycle regulation in lung cancer. *Front Oncol* 2020;10:1693.

131. Bailly C, Vergoten G. A new horizon for the old antibacterial drug clofocort. *Drug Discov Today* 2021;26:1302–10.

132. Hu Y, Zhang M, Tian N, Li D, Wu F, Hu P, et al. The antibiotic clofocort suppresses glioma stem cell proliferation by activating KLF13. *J Clin Invest* 2019;129:3072–85.

133. Rauschenbach L, Wieland A, Reintz R, Kebr S, Till A, Darkwa Oppong M, et al. Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma. *Eur J Cancer* 2020;140:130–9.

134. Marima R, Hull R, Dlaminzi Z, Penny C. Efavirenz and lopinavir/ritonavir alter cell cycle regulation in lung cancer. *Front Oncol* 2020;10:1693.